No retraction, correction or concern found when last checked on Oct 23, 2026.

The Extracellular Matrix: Its Composition, Function, Remodeling, and Role in Tumorigenesis

Kevin Dzobo, Collet Dandara

Biomimetics · 2023 · Review · CC BY

doi:10.3390/biomimetics8020146

Abstract

The extracellular matrix (ECM) is a ubiquitous member of the body and is key to the maintenance of tissue and organ integrity. Initially thought to be a bystander in many cellular processes, the extracellular matrix has been shown to have diverse components that regulate and activate many cellular processes and ultimately influence cell phenotype. Importantly, the ECM’s composition, architecture, and stiffness/elasticity influence cellular phenotypes. Under normal conditions and during development, the synthesized ECM constantly undergoes degradation and remodeling processes via the action of matrix proteases that maintain tissue homeostasis. In many pathological conditions including fibrosis and cancer, ECM synthesis, remodeling, and degradation is dysregulated, causing its integrity to be altered. Both physical and chemical cues from the ECM are sensed via receptors including integrins and play key roles in driving cellular proliferation and differentiation and in the progression of various diseases such as cancers. Advances in ‘omics’ technologies have seen an increase in studies focusing on bidirectional cell–matrix interactions, and here, we highlight the emerging knowledge on the role played by the ECM during normal development and in pathological conditions. This review summarizes current ECM-targeted therapies that can modify ECM tumors to overcome drug resistance and better cancer treatment.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 23, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1Tissues and organs in the human body are composed of cells, biomolecules as well as the extracellular matrix. The extracellular matrix (ECM) is key in many developmental stages from embryogenesis to adult development, and tissue repair as well as the maintenance of tissue and organ homeostasis. Once synthesized in the cytoplasm, ECM components are secreted into the extracellular space where they are then modified further into final molecules. The main recognized function of the ECM is the provision of physical support for cells within tissues and organs as well as availing the transportation of biomolecules such as growth factors and cytokines to cells. Recent reports indicate that the ECM is involved in the activation of several mechanosensitive signaling cascades and therefore impacts several cellular processes. The two forms of the ECM are the interstitial ECM and the basement membrane. This review mainly focuses on the interstitial matrix.

2The ECM is made up of several components that bond to form a complex network of different-sized molecules in a 3D unit (Figure 1). These ECM molecules are of different sizes, shapes, and spatial organization. Most tissues and organs have a specific type of ECM produced because of the differential expression of ECM genes as well as post-transcriptional splicing and post-translational modifications. The ECM is in most cases in a state of flux, changing over time because of tissue development and disease. Recent reports indicate that the ECM plays major role in disease progression and the development of chemoresistance. Whilst cells synthesize the ECM, the ECM has been referred to as the ‘theatre’ within which cells interact with each other and biomolecules to effectively determine how cells behave. Thus, cellular functions and phenotypes rely not just on gene expression but also on cues from the ECM.

3ECM remodeling under normal physiological conditions is a tightly controlled complex process, with many proteins playing different roles to maintain homeostasis. The ECM also undergoes remodeling during tumorigenesis, with several reports indicating that it can promote tumorigenesis as well as be antitumorigenic. In the early stages of tumor formation, stromal cells synthesize large amounts of ECM proteins in a bid to protect normal tissue from tumor cells. This results in the stiffening of the tissue around the newly formed tumor. The stiffening of the ECM is due to enhanced collagen as well as hyaluronic acid deposition. Chronic insult to a tissue results in the enhanced synthesis of ECM proteins, leading to a ‘fibrotic’ condition. Reports indicate that enhanced ECM deposition is positively correlated with tumor initiation and growth. Circulating tumor cells have been shown to hone and colonize tissues and organs displaying increased ECM synthesis. Both ECM proteins and the biomolecules found within the ECM have been identified as valuable markers for the diagnostic analysis of tumors. This review discusses ECM composition, function, and remodeling processes and presents evidence of several ECM components suggested as novel therapeutic targets and currently being investigated or undergoing validation.

2. The Extracellular Matrix Macromolecules

4The macromolecules found within tissues as well as organs that surround cells and provide tensile strength and other cues are what is termed the extracellular matrix. Various ‘omics’ studies have comprehensively identified ECM components, referred to as the ‘matrisome’, and more than 200 genes have been assigned in humans. The macromolecules form a fibrillar network that interacts with cells and biomolecules to influence cell behavior in tissues and organs. The exact number of extracellular matrix macromolecules in the human body is unknown. Two major classes of the ECMs are known: the tissue-specific ECM and interstitial ECM. The type and composition of the ECM vary depending on several factors including the tissue and organ of the body. There are several classes of ECM macromolecules including fibrillar collagens, filament-forming collagens and glycoproteins. Other classes include elastic proteins as well as proteoglycans. Important classes include the collagens that constitute the connective tissue. Under normal physiological conditions, the ECM is highly organized into sheets that confer tensile strength to tissues and organs. However, ECM composition may differ under conditions such as stress and diseases. The ECM also provides cues to cells via tethered biomolecules and ligands to effectively influence cell behavior.

3. Collagens

5The collagen family of proteins is the major component of the ECM and provides both mechanical strength and cues to cells and tissues. Reports indicate that collagens constitute around 90% of the ECM in humans. Thus, collagens influence many cellular processes in the body including proliferation, migration, and adhesion. Currently, about 28 proteins have been identified to belong to the collagen family. Being the major proteins in the ECM, collagens undergo multiple changes and remodeling throughout an animal’s growth and development and in pathological conditions such as wound healing and cancers. In addition, the synthesis of collagens requires modifications through the addition of disulfide bonds and other post-translational changes (Figure 2). Other ECM molecules also play a role in collagen synthesis and deposition. For example, the glycoprotein fibronectin is known to play a part in and influence the deposition and attachment of collagens in the extracellular space. The overall structure and organization of the ECM are therefore results of the interaction between its constituents including collagens, glycoproteins, and other molecules. Seven collagens have been grouped in the fibrillar class with type I collagen (or collagen type I) being a major component of this class. The other members include type II, type III, type V, type XI, type XXIV and type XXVII collagens. Most collagens that form part of the basement membrane are grouped in the network-forming collagen class and these include type IV, type VIII, type X, type XV and type XVIII collagens. Type VI and type XXVI collagens form the filament-forming class. The triple helical structure of some fibril-linked collagens can be interrupted and these include type IX, type XII, type XIV, type XVI, type XIX, and type XXII collagens. Other collagens family members are found within or bound to membranes and these include type XIII, type XVII, type XXII, type XXIII and type XXV collagens.

6Many studies have shown a link between changes in deposition and the amounts of collagens including the link between type I collagen and impaired development and the development of cancers. Collagens found within the ECM in normal tissues can be highly uniform in orientation whilst in pathological conditions the orientation is varied. Overall, the amounts of the different collagens in the ECM influence its properties from elasticity to availability of biomolecules such as growth factors and chemokines. Collagens within the ECM also play other important roles within the body. For example, collagens are important within basement membranes where they contribute towards the separation of different layers of tissues. Increased collagen deposition within basement membranes can lead to membrane hardening disrupting the normal exchange of biomolecules and movement of cells. In many pathological conditions such as cancer, basement membranes are thinner compared to normal tissues. This has been attributed to the reduced deposition of collagens including type IV, type XV, and type XIX collagens. Indeed, several in vitro studies have also shown that collagen knockdown can enhance the migration of cancer cells.

4. Other Extracellular Matrix Macromolecules

7A combination of proteins and carbohydrates make up glycoproteins and proteoglycans, with about 30 genes encoding these ECM components. The carbohydrates form repeating chains that are connected to a core made up of proteins. Proteoglycans are part of the glycoprotein family but are different from other glycoproteins in terms of their synthesis and structure. This ultimately influences their function in the body. Whilst glycoproteins have short and branched carbohydrate chains covalently linked to a protein core, the carbohydrate chains in proteoglycans are long and unbranched glycosaminoglycan chains also attached to a protein core. Glycoproteins’ side chains create enough of a buffer to allow the ECM to resist stress and forces applied to the ECM. In addition, glycoproteins are actively involved in regulating processes including proliferation and adhesion. The glycosaminoglycan chains of proteoglycans are also negatively charged, allowing proteoglycans to impact the organization of other ECM constituents. The negative charge of proteoglycans also allows the ECM as a whole to sequester growth factors and other biomolecules. Due to their size and structure, proteoglycans can also participate in the binding of ligands to receptors, allowing cells to respond to various changes in extracellular cues. Several signaling pathways including the AKT-MEK and PI3-Akt cascades are activated through the participation of proteoglycans in bonding to various receptors. The most well-known glycoproteins include fibronectin, fibrinogen, vitronectin, laminin, thrombospondins, periostin, and osteopontin. Among the well-known proteoglycans are decorin, aggrecan, and perlecan.

4.1. Laminin

8A glycoprotein consisting of α, β, and γ chains that come together to form trimeric proteins, laminin or laminins is/are found within the basal lamina and contribute towards cell-specific functions including differentiation, adhesion, and migration. Laminins as ECM glycoproteins play major roles in creating a link between the ECM and cells via binding to cellular receptors such as integrins. Thus, laminins are key to cellular migration and cancer cell invasive behavior. Currently, twelve mammalian chains (α, β and γ) have been identified, and these can combine in different amounts to form about sixty known laminins. The α chains (200 to 400 kDa) are bigger than the β and γ chains (120 to 200 kDa) with the trimer being formed ranging from 400 to 800 kDa in size. Referred to as the ‘god molecule’ in some reports, trimeric laminin has a ‘cross’ shape formed as a result of its α-helical coiled-coil structure. Laminins also bind to other ECM components including collagen type IV. In this case, laminins act as an intermediary or ‘glue’ between various ECM molecules within the basement membrane. Laminin polymerization is thought to be the main initiator of basement membrane assembly, placing laminin polymerization at the ‘center’ of cell function and tissue structure.

9A well-known laminin molecule is laminin-332 (LN-332), which is formed by β3, α3, and γ2 chains, plays key roles in cellular migration and adhesion and contributes to tumor cell metastasis. Laminin molecules are also implicated in maintaining stem cell self-renewal capabilities. For example, laminin-332 maintains CSCs’ self-renewal abilities and contributes to drug resistance. Several reports show that the presence of laminins is closely linked to significantly lower patient survival in cancers such as colorectal and pancreatic cancer. Laminins bind to other ECM proteins, and this promotes cell migration and adhesion as well as enhancing drug resistance. For example, the binding of laminin-332 to the integrin α3β1 receptor increases resistance to gefitinib in hepatocellular carcinoma. Various signaling cascades are also known to be activated through laminin–integrin interactions. For example, laminins’ interactions with integrins the cause activation of the mTOR cell survival signaling pathway.

4.2. Fibronectin

10Structurally, fibronectin (FN) has several domains and is involved in the interactions between the ECM and cells. Fibronectin forms a fibrillar network and is key to cell differentiation, adhesion, and migration. Fibronectin exists as a dimer of two molecules joined together via cysteine disulfide bonds. The assembly of fibronectin in the ECM occurs when it binds to α5β1 integrins via the RGD motif. Furthermore, the binding of fibronectin to integrins causes the clustering of integrin molecules, leading to increased levels of fibronectin molecules on the cell surface. Fibronectin-focal adhesion interactions alter the conformation of fibronectin, resulting in binding sites for other ECM molecules to be revealed. Fibronectin is therefore able to bind to collagens, laminins, and other proteins, allowing cells to adhere to the ECM and migrate. Whilst it is a single gene-encoded protein, it has several isoforms resulting in proteins that form ECM fibrillar structures. Fibronectin binds to cell surface receptors and other ECM proteins such as collagens causing alterations to cells’ actin filaments, and this allows cells to migrate. Various reports show that fibronectin is key in cellular processes such as wound healing as well as in tumor growth. Importantly, the adhesion of tumor cells to ECM proteins including fibronectin enhances the tumorigenic capacity of cancer cells as well as drug resistance. Various studies have also associated increased fibronectin expression with tumor progression in various cancers. Furthermore, clinical data associated enhanced fibronectin expression in tumors versus normal tissues with lower patient survival. FN-induced migration was shown to be mediated via αvβ6 and α9β1 integrins in various cancers. The binding of cancer cells to ECM proteins including fibronectin can protect cells from drug-induced apoptosis compared to cells attached to plastic. Fibronectin-mediated reduction in apoptosis occurs via the inducement of cyclooxygenase-2 (COX-2) as well as the activation of integrin α5β1. In addition, various signaling cascades are activated when fibronectin binds to other ECM proteins. The binding of cells to fibronectin also protects cells against many drug-induced states.

4.3. Periostin

11Periostin is an adhesion-linked protein expressed as an ECM protein and produced within the periosteum as well as the periodontal ligaments. It is a cell adhesion and nonstructural protein that functions to maintain tissue homeostasis, especially that of the tooth and bone tissues. It is mostly involved in many processes during development including cardiac development and healing but is expressed in low amounts in adult tissues. Periostin mediates most of its effects via interacting with surface receptors such as integrins. The enhanced expression of periostin is associated with various pathological conditions including inflammation and disease, and many types of cancer including colon, lung, and breast cancer, and head and neck carcinomas. Periostin is involved in regulating ECM–cell interactions via attachment to other ECM molecules including collagens, tenascin C, and fibronectin. Periostin can bind to various integrins such as αvβ3, αvβ5, and α6β4, and thus influence the activation of many signaling cascades. Some of the signaling cascades are Notch 1 and B-catenin signaling, which are important in cell differentiation and tissue specification. Various reports show that periostin is aberrantly expressed in pathological conditions such as arthritis, cancers, and fibrosis. In various cancers, periostin has been shown to induce signaling cascades including PI3K-Akt through attaching to αvβ3 and αvβ5 integrins. The presence of periostin enhances cancer cell proliferation and the process of EMT cancers such as gastric cancer. Cancer cells showing resistance to various drugs including cisplatin and 5-fluorouracil (5-FU) also show increased periostin expression. Thus, this suggests that increased periostin levels are correlated with drug resistance, tumor relapse, and tumor angiogenesis. Periostin activates Akt phosphorylation in cancers including epithelial and ovarian cancer and carcinoma and this results in resistance, especially to paclitaxel. Recent data suggest that periostin can be used as a prognostic marker in various cancers including pancreatic, ovarian, and esophageal cancers.

4.4. Hyaluronic Acid

12Discovered almost a century ago by Karl Meyer and John Palmer whilst working on vitreous bovine eyes, hyaluronic acid is a glycosaminoglycan made up of N-acetylglucosamine and glucuronic acid repeats and is a common component of the ECM. Hyaluronic acid is a long high-molecular-weight polymer with many hydroxyl moieties, allowing it to mix well in water. Indeed, one of the main functions of hyaluronic acid is to retain water in various tissues. Due to its size and the ability to form coils in water, hyaluronic acid can control the movement of biomolecules and ions within the ECM, allowing small molecules to pass whilst blocking the free movement or transport of larger biomolecules and substances. Hyaluronic acid displays various unique properties such as biodegradability and great viscoelasticity, and has been utilized in various applications such as hydrogel formation and drug delivery systems. Various studies have shown that hyaluronic acid plays crucial roles in cell migration and invasion through its interaction with receptors including CD44 and hyaluronan binding protein 4.

5. Extracellular Matrix Function

13The most important function of the ECM is providing an anchorage stage to cells as this is key to the maintenance of cell division and polarity. No longer is the ECM seen as only a scaffold necessary for cell structure, but also as a structure that provides both biophysical and biochemical cues to cells. In addition, the ECM can regulate cellular attachment and migration. Several pieces of evidence also show that the ECM can sequester growth factors and other biomolecules, and these are released at specific stages of development and disease progression to influence cell behavior and phenotype. During development, sequestered factors can cause gradients in biomolecule concentrations, and this is important during changes in tissue form and structure. Furthermore, secreted factors are involved in the activation of various signaling cascades and influence focal adhesion formations.

14The development of an organism from an embryo to an adult involves a lot of ECM changes, both in terms of quantity and type. These changes must be controlled tightly at each stage of development to avoid overregulation and downregulation which can have deleterious effects. ECM physical properties including topography, elasticity, and rigidity influence cell proliferation and differentiation and ultimately influence tissue structure and integrity.

15An important function of the ECM is that of aiding cell migration. For cells to migrate, their binding to the ECM via integrins and cadherins must occur first. Integrins allow cells to attach to various ECM molecules including collagens, fibronectin, and laminins. Integrins can then influence the intracellular actin cytoskeleton via focal adhesion proteins including talins and vinculins. ECM alignment and topography have been shown to influence both the speed of cell migration and the direction of migration. To influence cell migration in a specific direction, scientists have utilized specific ECM molecules as well as ECM gradients. Studies have shown that cells tend to migrate from low ECM concentration areas to areas of high ECM concentration, but this is not always the case. The migration of cells is characterized by repeated adhesion to the ECM as well as deadhesion from the ECM. Therefore, the rate of cell migration is dependent on various ECM properties including composition, alignment, and elasticity. Our earlier publication demonstrated that cells migrate slower in ECMs lacking collagens compared to in collagen-containing ECMs. ECM stiffness for example has been shown to influence cellular migration. Investigations are under way to identify specific ECM components required for cell differentiation and migration during development as the ECM is constantly being remodeled. Importantly, for cells to migrate and invade surrounding tissues, the action of matrix metalloproteases and other proteases that can degrade the ECM is necessary.

16The development of organs and tissues in the body is dependent on the presence of ECM proteins. For example, for the process of branching to occur, ECM proteins such as collagens and laminins are required to provide the anchor on which the formation of tubes can take place whilst ECM molecules such as hyaluronic acid allow epithelial cells to continue to migrate at the end bud. The ECM’s alignment and architecture help in controlling tissue formation and branching patterns. When a bud continues to grow, the ECM at the end is degraded, allowing various biomolecules including growth factors, cytokines, and chemokines to be released. The released factors in turn influence the rate of branching and the direction of the bud. The presence of the ECM at the end bud also means that various growth factors and signaling molecules can be sequestered and released at specific times when needed. Whilst ECM proteins are important during budding, specific ECM proteins are required to stop the growth of the bud. For example, the deposition of type I collagen leads to the termination of the growth of the bud. In summary, the ECM plays major roles during tissue and organ formation as well as in the formation of tubular structures. Importantly, in addition to the provision of a scaffolding on which tissues and organs can form, the ECM acts as a reservoir of various biomolecules needed by cells at specific times for differentiation and proliferation.

17Various studies have shown that the ECM induce cellular differentiation through the release of tethered factors as well as the physical structure and composition of the ECM. To study the effect of ECM composition on cell fate, we cultured fibroblasts on a fibroblast-derived ECM (fd-ECM) and showed that these fibroblasts downregulated type I collagen synthesis compared to controls. Via the use of function-blocking antibodies, our study demonstrated that the blockage of type I collagen gene expression in the presence of the ECM is mediated via integrins including α2β1. In addition, the same study revealed that ECM-mediated reduction in collagen was activated through the Ras-MEK/ERK signaling pathway. Importantly, through a deletion analysis of the COL1A2 promoter, our study showed the presence of an ECM-responsive element within the -375 and -107 regions. This study and other published reports demonstrate that ECM composition plays pivotal roles in determining cellular gene expression and function. Using a different approach, we also investigated the fate of adipose-derived MSCs (ad-MSCs) when cultured on a cell-derived ECM (cd-ECM). The reason for use of the cd-ECM in this case was to model the in vivo physiological microenvironment. Our data showed that ad-MSCs cultured in the ECM lost their multipotency and differentiated into the chondrogenic cellular lineage compared to controls. Elaborate studies including loss of function studies showed that cells can sense the mechanical environment and activate the Notch1 and β-catenin signaling cascades needed for ECM-mediated ad-MSCs chondrogenesis. Thus, ad-MSCs must sense the mechanical environment of the ECM to undergo chondrogenesis, proving that the ECM can induce the differentiation of cells.

18The process of maintaining tissue homeostasis requires the ECM to be constantly altered as cells undergo proliferation and differentiation. Once differentiated, cells must maintain their phenotypes whilst changes to tissues occur including the formation of new blood vessels. A bidirectional interaction exists between cells and the ECM. In a classic study of the interaction between cells and the ECM, we demonstrated that cells can ‘feel’ the presence of ECM components and other ECM properties through integrins including α2β1 and adjust the gene expression of ECM proteins based on cues from the ECM. Thus, a feedback process allows communication between the ECM and cells and is important to maintaining tissue homeostasis. Once this feedback mechanism is altered and unable to keep ECM degradation and deposition in check, conditions such as cancer can develop. Other ECM properties including elasticity also influence cell behavior. For example, Zhang and colleagues showed that ECM elasticity impacts then osteocyte gap junction elongation and also demonstrated the involvement of paxillin in signal transduction.

19Various techniques have been utilized to study the role of the ECM during development and in tumorigenesis. The most common technique involves ECM gene knockout, downregulation, and upregulation, leading to the alteration of ECM composition. The addition of enzymes that can degrade specific ECM proteins can also be used to alter ECM composition and reveal the role of specific proteins in various cellular processes. Antibodies against ECM proteins and their respective receptors including integrins can be used to investigate the role of ECM proteins in the development and maintenance of homeostasis. In our earlier publication, we showed that function-blocking antibodies used to downregulate collagen gene expression revealed that type I collagen interacts with α2β1 integrin. Other techniques that can be used to study ECM proteins’ role in development and tumorigenesis include the use of a three-dimensional culture, atomic force microscopy, and ECM protein crosslinking.

20Studying the composition of a tissue and organ ECM is challenging due to its complexity. ECM molecules are large and undergo further modifications, such as hydroxylation, glycation, and glycosylation. To profile ECM composition, various methods, and assays have been developed, including SDS-PAGE, to separate ECM proteins, followed by HPLC and mass spectrometry. Choosing the ideal sample preparation and identification steps are crucial for successful ECM analysis. Tailored experimental and analytical approaches are needed to decipher the complexity of the ECM with ECM molecules displaying different solubilities and post-translational modifications. Various methods have been used to solubilize the ECM, ranging from the use of 5 M Guanidine-HCL to 8M urea and 100mM DTT. The challenge lies in solubilizing ECM proteins without degrading them, and different methods can be used, ranging from the use of harsh solutions to the use of gentle solubilization.

21To obtain more ECM proteins, various methods can be used for sample preparation, such as the use of different-strength detergents, enzymatic digestion, or a photocleavable detergent called azo which can be used in the fractionation approach to characterize the ECM composition of tumors. There is no best method for ECM sample preparation, and scientists often use less harsh solutions to identify many ECM proteins. ECM proteomics has adopted methods used for global proteomics, such as TMT and iTRAQ for the accurate determination of protein abundance, and peptide fractionation using high-pH reversed-phase LC. Methods such as data-dependent acquisition are the major methods used for ECM profiling, and recent studies have also employed data-independent acquisition. To accurately identify and estimate protein abundance, it is important to maximize peptide-to-spectrum matching as well as the use of standards. Most importantly, various resources are available for scientists in ECM research. These include various databases and websites such as the MatrisomeDB (https://matrisomedb.org/ (accessed on 23 October 2022)), TopFIND (https://topfind.clip.msl.ubc.ca/ (accessed on 12 June 2022)), MatriNet (https://www.matrinet.org/ (accessed on 20 August 2022)) and The Manchester Peptide Location Fingerprinting website (https://www.manchesterproteome.manchester.ac.uk/#/MPLF (accessed on 8 May 2022)).

6. Extracellular Matrix Modifications

22The composition of the ECM in a specific location or tissue is influenced by several parameters such as the synthesis and degradation of its components. In addition, the biomolecules found within the ECM are location- or tissue-specific and are influenced to a large extent by resident stromal cells such as fibroblasts and immune cells. Further changes in ECM composition and the biomolecules found within it are brought about by the action of enzymes including matrix metalloproteases and hydroxylases. Studies in various cancers including breast and bladder cancers have shown that the post-translational hydroxylation of collagens leads to increased crosslinking and is linked to low patient survival. The crosslinking of ECM components, sulfation as well as glycosylation are some of the further changes that occur to ECM components after synthesis. These post-translational changes impact ECM components’ interactions with other members of the ECM as well as with receptors on cell surfaces. Whilst changes in ECM composition and sequestered biomolecules are necessary for tissue homeostasis, the state of lax is also necessary for development and growth. Altered synthesis and accumulation of any one component of the ECM can alter the existing delicate process of homeostasis and lead to conditions including fibrosis and the promotion of cancer growth. The contribution of stromal cells and immune cells has been recognized as key to the maintenance of homeostasis and the development of several pathological conditions.

23Reports indicate that when there is enhanced crosslinking of the ECM, a dense meshwork of ECM components is formed, leading to fibrosis and other pathological conditions. Importantly, the accumulation of ECM proteins leads to stiffening, which influences ECM-receptor interactions and cellular signaling. Excessively crosslinked ECM proteins also lead to reduced ECM turnover, allowing some ECM proteins to prolong their presence within certain tissues. For example, ECM proteins known to promote wound healing via their participation in certain stages of the process may prolong their presence around the wound, leading to an aberrant process. Various enzymes are known to take part in ECM crosslinking, and these include lysyl oxidases, and transglutaminases. The lysyl oxidase family of enzymes allows the deposition and accumulation of collagens and elastins in the ECM, and this has significant implications for cell morphology and movement. By influencing the deposition of collagens in the ECM, lysyl oxidases also affect cellular signaling and the response to therapy. Transglutaminases are enzymes involved in glutamine deamination during ECM protein and glycoprotein synthesis. Transglutaminases are also involved in transamidating glutamine residues during ECM synthesis and the proper alignment of fibers during ECM synthesis. The alignment of fibers by transglutaminases leads to ECM stiffening and a reduction in proteolytic degradation. A stiff ECM influences ECM-receptor interactions including integrin-mediated signaling. Another form of spontaneous ECM crosslinking is glycation, a process including Amadori rearrangement and Schiff base adduct formation. This process does not involve enzymes.

24The glycosylation of ECM molecules has been linked to various processes of tumorigenesis. For example, the enhanced glycosylation of fibronectin leads to increased EMT and high levels of invasive cell behavior in prostate cancer cells and carcinomas, respectively. The inhibition of integrin glycosylation including that of αvβ6 integrin leads to the enhanced invasive behavior of cells involved in metastasis. Demonstrating the importance of fibronectin as a component of the ECM, the phosphorylation of fibronectin leads to increased mechanical forces being needed for cell adhesion in various cancers. Glycosaminoglycans can undergo sulphation in various cancers, and this impacts cell–matrix signaling.

7. Proteolytic Degradation of the Extracellular Matrix

25Homeostasis involves the constant synthesis and degradation of ECM components over time. Enhanced or reduced synthesis and degradation beyond what is normal can lead to several pathological states including fibrosis. Many enzymes are involved in both the synthesis and degradation of the ECM. Importantly, ECM degradation is controlled by zinc-containing endopeptidases including matrix metalloproteinases and a disintegrin and metalloproteinase proteins with thrombospondin motifs (ADAMTSs). Excessive ECM degradation can lead to an abnormal ECM characterized by unbalanced ECM components or ECM components that are not crosslinked properly. The occurrence of more ECM degradation than synthesis can result in the removal of whole tissue components such as that of basement membranes and the vasculature, allowing cells to migrate in an uncontrolled manner. The levels of growth factors and cytokines previously bound to ECM proteins can increase locally due to excessive ECM degradation, leading to the unregulated activation of signaling cascades. For example, TGF-b and VEGF have been shown to be released from degraded ECM proteins through the action of MMPs, leading to the activation of various signaling cascades and angiogenesis. Inorganic ions including calcium ions can also be released from the degraded ECM, leading to the activation of calcium-dependent MMPs.

26One major class of enzymes involved in ECM degradation is that of matrix metalloproteinases (MMPs). As reviewed by Kesenbrock and colleagues, human MMPs are made up of a total of 23 enzymes with a Zn-containing domain as well as four hemopexin-like domains. Four MMP members, namely MMP14, MMP15, MMP16 and MMP24, contain both a transmembrane and cytoplasmic domain. Through degrading the ECM, MMPs impact cellular processes via the release of sequestered growth factors and cytokines. Whilst most MMPs have a specific substrate leading to their grouping as collagenases and gelatinases for example, many other MMPs cannot be grouped this way. Due to their actions in the body, MMPs are highly regulated to ensure the maintenance of homeostasis as well as to allow growth and development. The unregulated expression and the eventual action of MMPs have been associated with many pathological conditions. For example, MMP2 and MMP11 are associated with poor survival in ovarian cancer. However, some MMPs including MMP8 have been associated with increased survival in oral squamous cell carcinoma patients. The varied and sometimes opposing actions of MMPs in the body require derailed efforts to develop inhibitors for these enzymes.

27There are 21 disintegrin and metalloproteinase proteins (ADAMs) and about 19 ADAMs with thrombospondin motifs (ADAMTSs) in humans that play a role in degrading the basement membrane of vascular system vessels. Many ECM proteins and proteoglycans including collagens, fibronectin and vitronectin are degraded by ADAMs. ADAMTSs are secreted enzymes and involved in degrading proteoglycans and collagens. Several signaling cascades have been shown to be influenced by Adamalysins through the removal of ligands from the cell surface.

28Cathepsins are a family of ECM-degrading enzymes made up of 11 serine, cysteine, and aspartic peptidases. Cathepsins are mostly found in lysosomes and involved in the degradation of protein precursors such as procollagens within the cell. Cathepsins have been implicated in altered homeostasis and many pathological conditions including scar formation and cancer development and metastasis. On the contrary, cathepsin B is important during tissue regeneration in wounded human epidermal keratinocytes.

29Originally referred to as procollagen C-proteinases, bone morphogenetic protein I and tolloid-like proteinases are enzymes that play key roles in the maturation of procollagen molecules and have no known role in ECM degradation. These enzymes can cleave the carboxy terminus of procollagens, leading to the maturation of the procollagen molecules into collagens. These proteinases work in cahoots with growth factors in promoting ECM deposition during growth and development. Bone morphogenetic protein I and tolloid-like proteinases are essential in skin wound healing but their upregulation is linked to corneal scarring.

30Hyaluronidases are involved in the degradation of hyaluronan in the body to maintain tissue homeostasis. Hyaluronan is rapidly degraded after synthesis compared to other ECM components, and this is essential for tissue homeostasis. The accumulation of hyaluronan as well as its increased degradation are often associated with several pathological conditions including cancers. Additional enzymes, CEMIP and transmembrane protein 2, are also referred to as hyaluronidases, and the increased activity of hyaluronidases can lead to the formation of hyaluronan fragments that have been linked with the increased formation of blood vessels. Hyaluronan fragments, resulting from enhanced hyaluronan degradation, have also been linked to the increased synthesis and release of chemokines and cytokines, leading to the activation of various signaling cascades. Reports indicate that hyaluronan fragments accumulate during injury and lead to increased inflammatory factors being synthesized by immune cells around a wound. The persistent inflammation occurring as a result of the lack of removal of hyaluronan and its fragments can lead to the promotion of tumorigenesis. Dysregulated hyaluronan production disrupts the normal ECM structure as well as the formation of blood vessels. The main hyaluronan receptor is CD44 and it is involved in the removal of hyaluronan and its fragments in case of injury.

31Heparin sulfate glycosaminoglycans (HSGs) are cleaved by heparinase from proteoglycan core proteins and eventually degraded into oligosaccharides. HSGs are involved in ECM organization and the activation of cell signaling via their binding to other ECM components as well as receptors. Heparanase has been associated with enhanced wound healing and angiogenesis in various animal models. However, its overexpression has been linked to other pathological conditions including cancers. The disruption of normal heparinase expression causes ECM–heparan sulfate interactions to be altered, leading to weak ECM structures. Cell movement can be increased under these conditions as ‘pores’ are present in the ECM, and these allow cells to migrate easily.

32To maintain a normal ECM structure and the number of components, ECM-degrading enzymes are tightly regulated by the action of their respective inhibitors. Inhibitors of ECM degrading enzymes are secreted by various cells, and they act in both autocrine and paracrine modes. Some of the well-known inhibitors of ECM-degrading enzymes are the tissue inhibitors of metalloproteinases and cystanins. One of the well-known endogenous inhibitors of MMPs is the tissue inhibitors of the metalloproteinase (TIMP) family. In mammals, this family has four members, namely TIMP1, TIMP2, TIMP3, and TIMP4. TIMPs have recently been shown to inhibit the Adamalysin family of ECM proteinases, expanding their role in maintaining ECM homeostasis. Disruption in TIMP synthesis and secretion has been noted in many pathological conditions including cancers and aberrant wound healing.

33The action of cathepsins is reversibly inhibited by cystatins. Cystatins have both intracellular and extracellular activities and therefore influence both ECM synthesis and the remodeling of mature ECMs. Cystatins are also known to show inhibitory activities against papain and legumains. Serine and cysteine proteases involved in the degradation of various ECM proteins and proteoglycans can be irreversibly inhibited by serpins. Serpins play a significant role in maintaining tissue and vascular homeostasis as well as in fibrinolysis. Serpins have also been shown to play key roles in thrombosis. Serpins are part of a large family and therefore have many contrasting roles in mammals. Several ECM molecules contain structures called cryptic domains that release fragments called ‘matricryptins’ when the molecules are cleaved. These ‘matricryptins’ are important for cell adhesion and differentiation. Due to their many functions, some ‘matricryptins’ may serve as enzyme inhibitors and abrogate proteolytic activities, thus influencing ECM synthesis and degradation. One ‘matricryptin’ derived from the collagen XVIII molecule is Endostatin which has been shown to cripple the function of androgen receptor. Included in the matricryptins derived from collagen are arresten, tumstatin and canstatin, and these have been associated with many pathological conditions. Several matricryptins have been shown to have antigrowth properties and can cause senescence in cells, but evidence also points to the fact that a ‘matricryptins’ fragment from ECM molecules such as laminin 111 can promote cellular growth.

8. Fibroblasts and Extracellular Matrix Remodeling

34The unregulated synthesis and deposition of the extracellular matrix which is associated with many cancers results in fibrosis or the so-called ‘hardening’ associated with mostly advanced tumors (Figure 3). Whilst all stromal cells contribute towards the synthesis and deposition of the ECM, cancer-associated fibroblasts are the main cells carrying out this job. In addition, recent reports indicate that cancer cells also synthesize and deposit ECM proteins and proteoglycans. Similarities have been noted between the cancer-associated fibroblasts and fibroblasts found during wound healing. Cancer-associated fibroblasts display great heterogeneity and different cells have been suggested as sources of CAFs. Both local and recruited cells are potential sources of CAFs. For example, local fibroblasts can easily be recruited to growing tumors where they undergo the activation of CAFs. Mesenchymal stem cells from the bone marrow as well as adipose tissue are transformed into CAFs. The activation of local fibroblasts and transformation of other cells into CAFs are driven by growth factors and chemokines released by both cancer cells and stromal cells. Such growth factors and chemokines can be released within the vicinity of the cells or can be transported via exosomes from distant environments.

35Studies show that the presence of CAF presence and the increased synthesis and deposition of ECM are linked to the recurrence of disease and decreased patient survival. Research into which subset of CAFs drive tumorigenesis and the recurrence of disease is needed as great heterogeneity is displayed by CAFs, with some subsets of CAFs being known to be involved in inflammation whilst others being known to be myofibroblast-like, for example. Attempts have been made to characterize and classify CAFs, but the jury is out on the utility of such endeavors. In addition to the phenotypical differences displayed by CAFs, their precise location in the body and tumors also determine the role they play in various processes. Thus, CAF subsets release different growth factors and chemokines depending on their spatial location. Data are lacking on the changeability of the different CAF subsets and the contribution of the different subsets to tumorigenesis and disease outcomes. Since CAFs, other stromal cells and cancer cells contribute to the ECM and biomolecules found within tumors, it is currently difficult to assign a specific role to CAF-derived, stromal cell- and cancer-derived ECM molecules in disease progression and outcomes. Cancer cells within tumors for example have also been shown to synthesize unusual ECM proteins and proteoglycans that may play a role in fibrosis and disease progression.

36Hyperactivation of the sympathetic nervous system due to cellular stress is associated with the remodeling of the stroma. Furthermore, cellular stress has been shown to promote the synthesis and release of ECM molecules such as collagens. Increased ECM synthesis is linked to the development of chemoresistance in various cancers. For tumor cells to migrate and metastasize, there is need for space and the secretion of factors involved in invasion. ECM deposition is downregulated by tumor cells via the release of colony-stimulating factor 1. Reduced ECM synthesis leads to enhanced tumor cell invasion and migration. The specific contribution of ECM molecules, from either tumor cells or stromal cells to the progression of tumors is still a subject of intense research. In addition, the specific point when ECM molecules change from antitumorigenic to pro-tumorigenic ones and vice versa is not yet known. Another approach is to ‘normalize’ stromal cells involved in ECM synthesis, so that there is a normal production of ECM components.

9. Extracellular Matrix Signaling

37Tumorigenesis leads to alterations of the ECM in terms of structure and composition, with such alterations being pro-tumorigenic. Furthermore, such ECM alterations can also result in the development of chemoresistance. Cues from the ECM can be physical as well as sequestered biomolecules and these cause immediate as well as long term changes in gene expression. The turnover period of most ECM proteins and glycoproteins can be hours, days and weeks long and thus their continued presence provides a continuous stimulus to cells, leading to the activation of cellular cascades over a long time.

38Whilst stromal cells and tumor cells can both release growth factors and chemokines and thus influence signaling, the ECM can enhance or decrease the resulting signaling via the release of sequestered growth factors and chemokines and by sequestering synthesized factors, respectively. In addition, the stiffness of the ECM can influence integrin-based signaling during normal development and in diseases. Reports indicate that signaling cascades including the MEK-ERK and the JNK signaling cascades can be activated by ECM stiffening in various conditions. Other signaling cascades also respond to ECM composition and stiffness, thus targeting these signaling cascades together with targeting ECM composition and stiffness are plausible strategies to control tumorigenesis and metastasis.

39One of the major receptors of ECM-cell interactions is integrins. Integrins are heterodimers involved in transmitting extracellular cues into cellular signaling. During development and in some pathological conditions, specific integrins are expressed and these influence specific cellular activities such as migration, proliferation and adhesion. Importantly, the binding of various integrins including αvβ1, αvβ3 and α4β1 to ECM molecules has been linked with tumor cell invasion during tumorigenesis. The precise expression of certain integrins may be linked to the promotion of tumorigenesis, drug resistance and metastasis. The enhanced expression of α5β1 and its binding to the ECM molecule fibronectin has been linked to reduced drug efficacy in models of cancers. Overall, the involvement of integrins in development and pathological conditions such as cancers depends on the type of integrin, ECM molecules and cell type. The interconversion of integrins has also been associated with ‘cadherin switching’ during the epithelial to mesenchymal transition. The switching or conversion of integrins from one heterodimer to another is thought to be linked to their binding to different ECM ligands as well as to different cells.

40Several nonintegrin receptors are known to bind to ECM components and these include heparan sulfate proteoglycans bound to the surface of cells, the discoidin domain containing receptor 1 as well as leukocyte-associated immunoglobin-like receptor 1. Together with integrins, these receptors relay extracellular cues and signals to activate various signaling cascades. The activation of these nonintegrin ECM receptors in stromal and cancer cells can enhance ECM synthesis via a feedback loop, thereby decreasing the access of drugs to cancer cells. For example, syndecan 4 is highly expressed in various cancers and is known to activate signaling cascades associated with cancer cell survival. A major receptor for collagen and hyaluronic acid is CD44. Structurally, CD44 traverses the cell membrane and has both an extracellular domain and a cytoplasmic component. The interaction of CD44 and hyaluronic acid leads to the activation of various other receptors including EGFR and c-MET. Through the activation of signaling cascades, hyaluronic acid-CD44 plays a key role in tumorigenesis. The infiltration of lymphocytes into tumors is partly mediated by the interaction of CD44 with fibronectin, which allows lymphocytes to bind to fibronectin and other ECM components. CD44 has been reported to play key roles in tumorigenesis and its overexpression is linked to poor patient survival and drug resistance. CD44 is one of the important cancer stem cell markers in many cancers including colon cancer, breast cancer, prostate cancer, and lung cancer.

41External cues are sensed by receptors on the cell membrane and converted into cellular signaling to cause specific cellular behavior. This process is known as mechanotransduction and is important in various cellular processes, from those of normal development to those in diseases. Mechanotransduction influences all cells within tumors, ultimately determining the progression of tumor development. Whilst cells influence the deposition and accumulation of components of the extracellular matrix, extracellular matrix properties such as those of a mechanical nature and elasticity modulate cell behavior. Various signaling cascades are known to be activated by extracellular matrix-derived cues and these include MEK-ERK, PI3K-Akt and YAP-TAZ signaling.

42Cellular behavior is modulated not just by the amount of ECM components, but also by the biochemical properties of the ECM such as tensile strength, mechanoresistance, and elasticity. These biomechanical properties affect cellular processes such as cellular migration and metabolism. The adhesion of cells to the ECM of different elasticity shows that ECM elasticity influence gene expression and integrin levels on cell surfaces. In addition, cues and signaling molecules released during the adhesion of cells to the ECM influence the organization of the cytoskeleton and therefore affect cellular migration and invasive behavior. Various signaling cascades including FAK, and PI3K-Akt have been shown to modulate ECM–cell interactions, influencing normal cell growth and movement. An increase in ECM proteins including collagens has been associated with the migration of cells and the development of chemoresistance.

10. Extracellular Matrix and Cell Invasion and Metastasis

43Four major features of metastasis are the migration of cancer cells from their origin, their honing to new sites and the regulation of secondary sites in preparation for tumor growth, the heterogeneity of cancer cells and lastly the colonization of the new sites and growth of secondary tumors (Figure 4). At each stage of the metastatic process, the ECM plays a central role and its remodeling influences the progression of the process. The alignment of ECM proteins including collagens and fibronectin has been shown to influence tumor cell metastasis in various cancers. Linear collagen molecules appear to promote tumor cell migration as the spaces between fibers allow cancer cells to move in a certain direction. Furthermore, the action of both tumor- and stromal cell-derived MMPs in the degradation of ECM molecules allows spaces to be created for tumor cell migration and invasion into surrounding areas. ECM molecule post-translational modification processes including hydroxylation also promote metastasis by promoting the enhanced synthesis of ECM molecules. Due to their size and physical structures, ECM molecules can shield invading and migrating tumor cells from the effects of shear stress during the tortuous journey to secondary sites. One major feature of successful metastasis is the preparation of ‘new sites’ for tumor cells to colonize and grow. Various theories have been given to explain this process. For example, it is thought that tumor-derived MMPs degrade and remodel the existing ECM of the ‘new sites’ before tumor cells colonize these sites. Following the ‘seed and soil’ hypothesis, this remodeling of the existing ECM in new sites is important to create the right pro-tumorigenic environments for colonization by metastatic tumor cells. Overall, it is accepted that the ECM plays an important role in allowing metastatic tumor cells to colonize new sites and be able to grow. In other instances, tumor cells do not grow into secondary tumors but remain quiescent for some time. These tumor cells can survive for a long time, reawaken, and grow into tumors after a long time. For example, the upregulation of the ECM molecule periostin has been shown to promote the reawakening of breast cancer cells from dormancy.

11. Extracellular Matrix in Drug Resistance: The Extracellular Matrix Shields Tumor Cells from Anti-Cancer Drugs

44Studies reveal that the ECM is a major player in tumorigenesis and treatment outcomes. Furthermore, reports indicate that therapy itself can induce ECM remodeling and can result in molecule deposition within tumors. TGF-B levels have been associated with increased ECM remodeling induced by drugs. Increased levels of endogenous tissue inhibitors of metalloproteinases (TIMPs) are linked to positive clinical outcomes in many cancers. On the other hand, increased levels of receptors including integrins are linked to poor outcomes and disease recurrence. ECM stiffness impacts the adhesion of cells, movement of cells, and response to therapy. Increased matrix stiffness within tumors is linked to less responsive tumors and drug resistance (Figure 5). Generally, stiffer ECMs are found surrounding tumors compared to ECMs in normal tissues. ECM stiffness is linked to fibrosis in many cancers including breast cancer where it is observed that many signaling cascades are also activated. Furthermore, various reports indicate that a stiff TME promotes tumor progression via the activation of integrin signaling. Tumor metastasis is promoted by ECM stiffening via the action of lysyl oxidase and deposition of collagens. ECM stiffening can also induce microRNAs involved in the downregulation of the tumor suppressor protein PTEN. Drug delivery relies on diffusion and pressure within the interstitial spaces. The remodeling of the ECM can create a barrier to drug diffusion and either impede drug movement altogether or limit its movement and therefore reduce its effectiveness.

45The question on every scientist’s mind is whether or not the ECM is of relevance to disease initiation and progression beyond what is already known. An analysis of tumor biopsy samples has so far revealed normal and disease-specific ECM signatures in various cancers. Low levels of specific ECM molecules including decorin have been associated with poor patient’ survival in various cancers. The understanding of ECM composition and the amounts of components in it at different stages of tumorigenesis is valuable in disease targeting. Drugs can be designed to target or have great adherence to specific ECM molecules to deliver the drugs to specific tumor sites. Studies in various cancers have shown that specific cancers have a specific ECM signature that is predictive of patient survival, and the question is whether or not specific ECM proteins are pro-tumorigenic or antitumorigenic. Various in vitro studies have shown that the knockdown or removal of certain ECM proteins can sensitize cancer cells to drugs. Currently, the use of cancer-specific ECM signatures in treatment strategies is limited and requires a further detailed analysis of the ECM proteins at specific stages of tumorigenesis. Data from Senthebane and colleagues suggest that targeting fibrillar collagen and fibronectin in tumors may allow drugs to access tumor cells and therefore improve therapeutic efficiency.

46Many approaches have been utilized to block the pro-tumorigenic properties of the ECM. For example, stopping the expression of collagens and fibronectin leads to reduced drug resistance of cancer cells. Several ECM members are known to accumulate in various cancers, and their degradation in combination with chemotherapy can result in better outcomes for patients. Furthermore, since most ECM proteins require post-translational modifications for stability and to have the right conformation, the disruption of modifications can also result in unstable ECM proteins. This has a two-fold effect: a decrease in ECM components leads to less fibrosis and can lead to increased drug efficacy and reduced ECM components lead to fewer MMPs being required and present within the TME. The presence of fewer MMPs can reduce the aggressiveness of many cancers. It is important to note that inhibitors of MMP activities have given very disappointing results in many clinical trials. Part of the reason why MMP inhibitors did not succeed as expected is the presence of many members of the MMP family and their overlapping activities.

47In addition to targeting ECM components, many signaling cascades that are activated or downregulated by ECM proteins can be regulated. Various survival pathways are activated in various cancers. Many developed small-molecule inhibitors can abrogate cancer cell signaling, leading to induced drug sensitivity in cancer cells. Whilst studies using inhibitors of ECM synthesis and signaling give promising data, it is important to note that ECM components can have both pro-tumorigenic and antitumorigenic behavior. This complex behavior requires deep analysis, and many hurdles are still to be overcome.

12. Therapeutic Strategies Targeting the Extracellular Matrix

48Considerations of ECM composition as well as of genetic mutations have allowed the administration of drugs that target specific ECM molecules and specific organs, leading to improved patient outcomes. Important in this regard are new drugs that target specific ECM components, either to upregulate or downregulate their expression, as these can be used in combination with existing drugs. The total removal of specific ECM components may not be the best way forward as this can promote tumor progression and impact normal tissue function. In tumors, collagen levels can be regulated at different stages of their synthesis and degradation. Collagen levels can be controlled by targeting various signaling cascades involved in their synthesis such as TGF-B signaling. Antibodies including fresolimumab are currently under clinical trials in cancers where they are used to reduce collagen levels. The inhibition of TGF-B signaling through the use of halofuginone is effective at reducing collagen levels in various cancers. Other drugs used to target the TGF-B cascade include pirfenidone, metformin, tranilast and Ki26894. Caution is needed when inhibiting collagen levels via blocking the TGF-B signaling cascade as TGF-B is involved in other body processes such as inflammation. Another way to reduce collagen levels is to use collagenases. In normal tissues, collagenases can easily be made available to degrade collagen. In solid tumors that are compact, collagenases cannot be transported easily due to their large size. A major issue regarding degrading collagen within solid tumors is the potential release of sequestered growth factors, resulting in unintended effects. In addition, the degradation of any ECM component may create ‘highways’ for cancer cell migration and metastasis. MMPs can also be used to degrade ECM components such as collagen. The effectiveness of MMP use and of the use of their inhibitors in cancers has been disappointing with many clinical trials yielding no good results.

49Various cancer therapies have been used to target fibronectin and these include its potential as a drug delivery molecule. Reports indicate that fibronectin or its isoforms are upregulated in many cancer tissues as well as in normal tissues. Antibodies against fibronectin domains including L19 have been used to inhibit cancer cell growth. In addition, peptides that bind to the fibronectin domain EDB (extra domain B) can be used to deliver drugs and drug-containing exosomes to tumors resulting in the better shrinkage of tumors than can be achieved with just drugs alone. Another ECM protein that has been targeted during cancer therapy is hyaluronic acid. Hyaluronic acid synthesis can be inhibited by 4-methylumbelliferone. The inhibition of hyaluronic acid synthesis leads to the loss of tissue integrity, thus causing tumors to be leaky with no proper structure. Hyaluronic acid synthesis inhibition thus leads to more drugs reaching tumor cells compared to tumors with normal hyaluronic acid levels. Hyaluronic acid can also be degraded via the use of hyaluronidase. Various reports and clinical trials are underway to evaluate the usefulness of hyaluronidase in combination with drugs. Various integrins, expressed by cancer cells, can also be targeted in various cancers. The use of antibodies against integrins has shown great results in cancers including breast and colon cancers. Such anti-integrin antibodies include volociximab and vitaxin. Small-molecule integrin antagonists can target specific integrin–ECM interactions that can block integrin-mediated cancer cell migration and therefore prevent tumor cell invasion and metastasis. Such integrin antagonists include cilengitide. Antibodies against CD44 including bivatuzumab and RO5429083 have shown antitumor activity in patients with advanced cancers.

50ECM-targeted therapy involving biomimicry is a type of treatment that aims to mimic the natural structure and function of the ECM. Biomolecules and biomaterials are designed to replicate properties of the ECM such as its composition, mechanical properties and signaling cues. A common approach to ECM biomimicry involves using natural ECM components such as collagen, fibronectin, and laminins as building blocks for synthetic materials. A combination of these ECM components can create materials mimicking various natural ECM structures and functions. ECM biomimetics for cancer therapy has been used in the development of ECM-based scaffolds for drug delivery. The scaffolds are designed to mimic the structure and composition of a natural ECM and can therefore deliver drugs directly to tumor cells. The ECM-based scaffolds provide a physical barrier that protects drugs from possible degradation and clearance during circulation and thus allows drugs to reach tumor cells at the right concentration. This increases drug efficacy as well as reducing systemic toxicity. Knowledge of the ECM surrounding tumor cells can lead to tumor-specific drug uptake and enhances drug retention at the tumor site for more effective cancer treatment.

51ECM-based scaffolds can be used to support the growth and differentiation of stem cells which have been shown to differentiate into cell types including those that can destroy tumor cells. Stem cells can also be used to deliver anticancer drugs directly to tumor cells as well as generate new tissues to replace tissues damaged due to cancer or therapy. ECM mimicking scaffolds can also induce brown adipogenesis in mesenchymal stem cells, which have been shown to have potential antitumor properties. A bioinspired nanofiber scaffold mimicking the ECM structure of the spinal cord can lead to the regeneration of an injured spinal cord, a common side effect of cancer treatments. A promising area of ECM biomimetics for cancer therapy is the development of ECM-mimicking nanoparticles for targeted drug delivery. Nanoparticles can be designed to mimic the structure and function of the ECM, enhancing their ability to selectively target cancer cells expressing certain receptors or proteins. The nanoparticles can be loaded with therapeutic agents including small interfering RNAs (siRNAs) that selectively knockdown or knockout genes involved in tumor growth and metastasis. By targeting cancer cells only, ECM-mimicking nanoparticles can improve drug efficacy and reduce systemic toxicity.

52Furthermore, researchers are exploring the use of ECM-mimicking hydrogels for the delivery of immunotherapeutic agents. Immunotherapy has emerged as a promising approach in cancer treatment, stimulating the patient’s own immune system to recognize and attack cancer cells. ECM-mimicking hydrogels can be used to deliver immunotherapeutic agents, such as checkpoint inhibitors, directly to the tumor microenvironment, enhancing its ability to stimulate an immune response against cancer cells. Finally, ECM biomimetics is being studied for the development of new imaging techniques for cancer diagnosis and treatment monitoring. By mimicking the structure and composition of the ECM, these imaging techniques can provide high-resolution images of the TME, allowing clinicians to monitor both tumor growth and the response to therapy. This information can guide treatment decisions and optimize cancer treatment outcomes.

13. Conclusions

53The ECM exists in normal and tumor tissues. During development, the ECM performs functions including providing structural support for cells and directing cell differentiation. In tumors, the ECM is needed for giving continual support to the growing tumor mass as well as to promote tumor cell migration and metastasis. Over the years, new technologies and bioinformatic softwares have been developed to delve deeper into the composition of both normal and tumor ECMs, revealing that the ECM can be used in directing cellular function and in a diagnostic and predictive manner, for example. A better understanding of the ECM has led to efforts being made to interfere with its synthesis and degradation to improve patient outcomes. In its simplistic nature, targeting individual ECM proteins inadvertently affects other physiological processes and must be investigated further. Disruptions to ECM synthesis and degradation will impact tissue homeostasis, a complex state maintained by many interlinked processes. Importantly, merely disrupting ECM synthesis and degradation is not going to stop pathological conditions such as cancer from developing but is required to be combined with therapeutic strategies such as chemotherapy, immunotherapy, and radiotherapy. ECM biomimetics has the potential to revolutionize cancer therapy, providing new strategies for drug delivery, stem cell-based therapies, targeted immunotherapy, and cancer imaging. This calls for further deeper investigations of how multiple antitumor strategies can be combined to have synergistic or additive effects.

References 519

1.
Bissell M.J., Hall H.G., Parry G. How does the extracellular matrix direct gene expression? J. Theor. Biol. 1982;99:31-68.
Not in our library10.1016/0022-5193(82)90388-5
2.
Nelson C.M., Bissell M.J. Of extracellular matrix, scaffolds, and signaling: Tissue architecture regulates development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2006;22:287-309.
Not in our library10.1146/annurev.cellbio.22.010305.104315
3.
Role of Extracellular Matrix in Development and Cancer Progression · 2018
No notice
4.
Pupa S.M., Ménard S., Forti S., Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J. Cell. Physiol. 2002;192:259-267.
Not in our library10.1002/jcp.10142
5.
Clause K.C., Barker T.H. Extracellular matrix signaling in morphogenesis and repair. Curr. Opin. Biotechnol. 2013;24:830-833.
Not in our library10.1016/j.copbio.2013.04.011
6.
Dzobo K., Vogelsang M., Parker M.I. Wnt/β-catenin and MEK-ERK signaling are required for fibroblast-derived extracellular matrix-mediated endoderm differentiation of embryonic stem cells. Stem Cell Rev. Rep. 2015;11:761-773.
Not in our library10.1007/s12015-015-9598-4
7.
Dzobo K., Turnley T., Wishart A., Rowe A., Kallmeyer K., Van Vollenstee F.A., Thomford N.E., Dandara C., Chopera D., Pepper M.S. Fibroblast-derived extracellular matrix induces chondrogenic differentiation in human adipose-derived mesenchymal stromal/stem cells in vitro. Int. J. Mol. Sci. 2016;17:1259.
Not in our library10.3390/ijms17081259
8.
Yin H., Wang J., Li H., Yu Y., Wang X., Lu L., Lv C., Chang B., Jin W., Guo W., et al. Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness. Nat. Commun. 2021;12:4230.
Not in our library10.1038/s41467-021-24315-1
9.
Dussoyer M., Page A., Delolme F., Rousselle P., Nyström A., Moali C. Comparison of extracellular matrix enrichment protocols for the improved characterization of the skin matrisome by mass spectrometry. J. Proteom. 2022;251:104397.
Not in our library10.1016/j.jprot.2021.104397
10.
Mienaltowski M.J., Gonzales N.L., Beall J.M., Pechanec M.Y. Basic Structure, Physiology, and Biochemistry of Connective Tissues and Extracellular Matrix Collagens. Adv. Exp. Med. Biol. 2021;1348:5-43.
Not in our library10.1007/978-3-030-80614-9_2
11.
Giblin S.P., Schwenzer A., Midwood K.S. Alternative splicing controls cell lineage-specific responses to endogenous innate immune triggers within the extracellular matrix. Matrix Biol. 2020;93:95-114.
Not in our library10.1016/j.matbio.2020.06.003
12.
Chen W., Yuan Y., Li C., Mao H., Liu B., Jiang X. Modulating Tumor Extracellular Matrix by Simultaneous Inhibition of Two Cancer Cell Receptors. Adv. Mater. 2021;34:e2109376.
Not in our library10.1002/adma.202109376
13.
Gu X., Ge L., Ren B., Fang Y., Li Y., Wang Y., Xu H. Glucocorticoids Promote Extracellular Matrix Component Remodeling by Activating YAP in Human Retinal Capillary Endothelial Cells. Front. Cell Dev. Biol. 2021;9:738341.
Not in our library10.3389/fcell.2021.738341
14.
Laurito T.L., França F.T., Vieira-Damiani G., Pelegati V.B., Baratti M.O., de Carvalho H.F., Cesar C.L., de Moraes A.M., Cintra M.L., Teixeira F. The texture of collagen in the microenvironments of Merkel cell carcinoma. Medicine. 2021;100:e27925.
Not in our library10.1097/md.0000000000027925
15.
Dzobo K. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. Omics. 2020;24:175-179.
Not in our library10.1089/omi.2020.0019
16.
Dzobo K., Leaner V.D., Parker M.I. Feedback regulation of the α2(1) collagen gene via the Mek-Erk signaling pathway. IUBMB Life. 2012;64:87-98.
Not in our library10.1002/iub.568
17.
Senthebane D.A., Jonker T., Rowe A., Thomford N.E., Munro D., Dandara C., Wonkam A., Govender D., Calder B., Soares N.C., et al. The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices. Int. J. Mol. Sci. 2018;19:2861.
Not in our library10.3390/ijms19102861
18.
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer · 2017
No notice
19.
Cox T.R. The matrix in cancer. Nat. Rev. Cancer. 2021;21:217-238.
Not in our library10.1038/s41568-020-00329-7
20.
Lukashev M.E., Werb Z. ECM signalling: Orchestrating cell behaviour and misbehaviour. Trends Cell Biol. 1998;8:437-441.
Not in our library10.1016/s0962-8924(98)01362-2
21.
Ghajar C.M., Bissell M.J. Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: Insights from imaging. Histochem. Cell Biol. 2008;130:1105.
Not in our library10.1007/s00418-008-0537-1
22.
Dzobo K., Vogelsang M., Thomford N.E., Dandara C., Kallmeyer K., Pepper M.S., Parker M.I. Wharton’s Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro. Stem Cells Int. 2016;2016:4842134.
Not in our library10.1155/2016/4842134
23.
Vitale I., Manic G., Galassi C., Galluzzi L. Stress responses in stromal cells and tumor homeostasis. Pharmacol. Ther. 2019;200:55-68.
Not in our library10.1016/j.pharmthera.2019.04.004
24.
The Role of the Extracellular Matrix in Cancer Stemness · 2019
No notice
25.
The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited · 2023
No notice
26.
Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010;22:697-706.
Not in our library10.1016/j.ceb.2010.08.015
27.
Deegan D.B., Zimmerman C., Skardal A., Atala A., Shupe T.D. Stiffness of hyaluronic acid gels containing liver extracellular matrix supports human hepatocyte function and alters cell morphology. J. Mech. Behav. Biomed. Mater. 2016;55:87-103.
Not in our library10.1016/j.jmbbm.2015.10.016
28.
Cox T.R., Erler J.T. Molecular pathways: Connecting fibrosis and solid tumor metastasis. Clin. Cancer Res. 2014;20:3637-3643.
Not in our library10.1158/1078-0432.ccr-13-1059
29.
Piersma B., Hayward M.K., Weaver V.M. Fibrosis and cancer: A strained relationship. Biochim. Biophys. Acta Rev. Cancer. 2020;1873:188356.
Not in our library10.1016/j.bbcan.2020.188356
30.
Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2013;10:656-665.
Not in our library10.1038/nrgastro.2013.183
31.
Cox T.R., Bird D., Baker A.M., Barker H.E., Ho M.W., Lang G., Erler J.T. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73:1721-1732.
Not in our library10.1158/0008-5472.can-12-2233
32.
Choi S.K., Kim H.S., Jin T., Moon W.K. LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. Oncotarget. 2017;8:11977-11989.
Not in our library10.18632/oncotarget.14450
33.
Lysyl Oxidase and the Tumor Microenvironment · 2016
No notice
34.
Naba A., Clauser K.R., Ding H., Whittaker C.A., Carr S.A., Hynes R.O. The extracellular matrix: Tools and insights for the “omics” era. Matrix Biol. 2016;49:10-24.
Not in our library10.1016/j.matbio.2015.06.003
35.
Giussani M., Triulzi T., Sozzi G., Tagliabue E. Tumor extracellular matrix remodeling: New perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. Cells. 2019;8:81.
Not in our library10.3390/cells8020081
36.
Yang J.D., Nakamura I., Roberts L.R. The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets. Proceedings of the Seminars in Cancer Biology. 2011;35-43.
Not in our library10.1016/j.semcancer.2010.10.007
37.
Wood S.L., Pernemalm M., Crosbie P.A., Whetton A.D. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat. Rev. 2014;40:558-566.
Not in our library10.1016/j.ctrv.2013.10.001
38.
Zanconato F., Battilana G., Cordenonsi M., Piccolo S. YAP/TAZ as therapeutic targets in cancer. Curr. Opin. Pharmacol. 2016;29:26-33.
Not in our library10.1016/j.coph.2016.05.002
39.
Fuster M.M., Esko J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer. 2005;5:526-542.
Not in our library10.1038/nrc1649
40.
Extracellular matrix and its therapeutic potential for cancer treatment · 2021
No notice
41.
Hynes R.O., Naba A. Overview of the matrisome—An inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 2012;4:a004903.
Not in our library10.1101/cshperspect.a004903
42.
Parsons J.T., Horwitz A.R., Schwartz M.A. Cell adhesion: Integrating cytoskeletal dynamics and cellular tension. Nat. Rev. Mol. Cell Biol. 2010;11:633-643.
Not in our library10.1038/nrm2957
43.
Hynes R.O. The extracellular matrix: Not just pretty fibrils. Science. 2009;326:1216-1219.
Not in our library10.1126/science.1176009
44.
Collagen as a double-edged sword in tumor progression · 2013
No notice
45.
Ricard-Blum S. The collagen family. Cold Spring Harb. Perspect. Biol. 2011;3:a004978.
Not in our library10.1101/cshperspect.a004978
46.
Gay S., Vijanto J., Raekallio J., Penttinen R. Collagen types in early phases of wound healing in children. Acta Chir. Scand. 1978;144:205-211.
Not in our library
47.
Singh S., Young A., McNaught C.-E. The physiology of wound healing. Surgery. 2017;35:473-477.
Not in our library10.1016/j.mpsur.2017.06.004
48.
Dzobo K. Matrix-Mediated Regulation of Type 1 Collagen Synthesis and Degradation in Cultured Fibroblasts. Ph.D. Thesis. 2009.
Not in our library
49.
Scott I., Yamauchi M., Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012;52:113-133.
Not in our library10.1042/bse0520113
50.
Garnero P., Borel O., Gineyts E., Duboeuf F., Solberg H., Bouxsein M.L., Christiansen C., Delmas P.D. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone. 2006;38:300-309.
Not in our library10.1016/j.bone.2005.09.014
51.
Sottile J., Shi F., Rublyevska I., Chiang H.-Y., Lust J., Chandler J. Fibronectin-dependent collagen I deposition modulates the cell response to fibronectin. Am. J. Physiol. Cell Physiol. 2007;293:C1934-C1946.
Not in our library10.1152/ajpcell.00130.2007
52.
Mechanical forces regulate the interactions of fibronectin and collagen I in extracellular matrix · 2015
No notice
53.
Dzobo K., Leaner V.D., Parker M.I. Absence of feedback regulation in the synthesis of COL1A1. Life Sci. 2014;103:25-33.
Not in our library10.1016/j.lfs.2014.03.006
54.
Chelyshev Y.A., Kabdesh I.M., Mukhamedshina Y.O. Extracellular Matrix in Neural Plasticity and Regeneration. Cell. Mol. Neurobiol. 2020.
Not in our library10.1007/s10571-020-00986-0
55.
Hastings J.F., Skhinas J.N., Fey D., Croucher D.R., Cox T.R. The extracellular matrix as a key regulator of intracellular signalling networks. Br. J. Pharmacol. 2019;176:82-92.
Not in our library10.1111/bph.14195
56.
Collagen reorganization at the tumor-stromal interface facilitates local invasion · 2006
No notice
57.
Amatangelo M.D., Bassi D.E., Klein-Szanto A.J., Cukierman E. Stroma-derived three-dimensional matrices are necessary and sufficient to promote desmoplastic differentiation of normal fibroblasts. Am. J. Pathol. 2005;167:475-488.
Not in our library10.1016/s0002-9440(10)62991-4
58.
Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010;123:4195-4200.
Not in our library10.1242/jcs.023820
59.
Hay E.D. Cell Biology of Extracellular Matrix. 2013.
Not in our library
60.
Sonbol H.S. Extracellular matrix remodeling in human disease. J. Microsc. Ultrastruct. 2018;6:123.
Not in our library10.4103/jmau.jmau_4_18
61.
Candiello J., Balasubramani M., Schreiber E.M., Cole G.J., Mayer U., Halfter W., Lin H. Biomechanical properties of native basement membranes. FEBS J. 2007;274:2897-2908.
Not in our library10.1111/j.1742-4658.2007.05823.x
62.
Amenta P.S., Briggs K., Xu K., Gamboa E., Jukkola A.F., Li D., Myers J.C. Type XV collagen in human colonic adenocarcinomas has a different distribution than other basement membrane zone proteins. Hum. Pathol. 2000;31:359-366.
Not in our library10.1016/s0046-8177(00)80251-8
63.
Tosios K., Kapranos N., Papanicolaou S. Loss of basement membrane components laminin and type IV collagen parallels the progression of oral epithelial neoplasia. Histopathology. 1998;33:261-268.
Not in our library10.1046/j.1365-2559.1998.00452.x
64.
Spivey K.A., Chung I., Banyard J., Adini I., Feldman H.A., Zetter B.R. A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis. Oncogene. 2012;31:2362-2372.
Not in our library10.1038/onc.2011.406
65.
Madsen C.D. Pancreatic cancer is suppressed by fibroblast-derived collagen I. Cancer Cell. 2021;39:451-453.
Not in our library10.1016/j.ccell.2021.02.017
66.
Kresse H., Schönherr E. Proteoglycans of the extracellular matrix and growth control. J. Cell. Physiol. 2001;189:266-274.
Not in our library10.1002/jcp.10030
67.
Lee K., Loganathan D., Merchant Z., Linhardt R. Carbohydrate analysis of glycoproteins A review. Appl. Biochem. Biotechnol. 1990;23:53-80.
Not in our library10.1007/bf02942052
68.
Hughes R.C. Membrane Glycoproteins: A Review of Structure and Function. 2014.
Not in our library
69.
Iozzo R.V., Schaefer L. Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11-55.
Not in our library10.1016/j.matbio.2015.02.003
70.
Hardingham T.E., Fosang A.J. Proteoglycans: Many forms and many functions. FASEB J. 1992;6:861-870.
Not in our library10.1096/fasebj.6.3.1740236
71.
Iozzo R.V. Matrix proteoglycans: From molecular design to cellular function. Annu. Rev. Biochem. 1998;67:609-652.
Not in our library10.1146/annurev.biochem.67.1.609
72.
Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing · 2018
No notice
73.
Broekelmann T.J., Bodmer N.K., Mecham R.P. Identification of the growth factor—Binding sequence in the extracellular matrix protein MAGP-1. J. Biol. Chem. 2020;295:2687-2697.
Not in our library10.1074/jbc.ra119.010540
74.
Bohaumilitzky L., Huber A.K., Stork E.M., Wengert S., Woelfl F., Boehm H. A Trickster in Disguise: Hyaluronan’s Ambivalent Roles in the Matrix. Front. Oncol. 2017;7:242.
Not in our library10.3389/fonc.2017.00242
75.
Price Z.K., Lokman N.A., Ricciardelli C. Differing roles of hyaluronan molecular weight on cancer cell behavior and chemotherapy resistance. Cancers. 2018;10:482.
Not in our library10.3390/cancers10120482
76.
Januchowski R., Zawierucha P., Ruciński M., Nowicki M., Zabel M. Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line. BioMed Res. Int. 2014;2014:365867.
Not in our library10.1155/2014/365867
77.
Timpl R., Rohde H., Robey P.G., Rennard S.I., Foidart J.M., Martin G.R. Laminin—A glycoprotein from basement membranes. J. Biol. Chem. 1979;254:9933-9937.
Not in our library10.1016/s0021-9258(19)83607-4
78.
Hohenester E., Yurchenco P.D. Laminins in basement membrane assembly. Cell Adhes. Migr. 2013;7:56-63.
Not in our library10.4161/cam.21831
79.
Domogatskaya A., Rodin S., Tryggvason K. Functional diversity of laminins. Annu. Rev. Cell Dev. Biol. 2012;28:523-553.
Not in our library10.1146/annurev-cellbio-101011-155750
80.
Hohenester E. Structural biology of laminins. Essays Biochem. 2019;63:285-295.
Not in our library10.1042/ebc20180075
81.
Aumailley M. The laminin family. Cell Adh. Migr. 2013;7:48-55.
Not in our library10.4161/cam.22826
82.
Fukazawa S., Shinto E., Tsuda H., Ueno H., Shikina A., Kajiwara Y., Yamamoto J., Hase K. Laminin β3 expression as a prognostic factor and a predictive marker of chemoresistance in colorectal cancer. Jpn. J. Clin. Oncol. 2015;45:533-540.
Not in our library10.1093/jjco/hyv037
83.
Govaere O., Wouters J., Petz M., Vandewynckel Y.P., Van den Eynde K., Van den Broeck A., Verhulst S., Dolle L., Gremeaux L., Ceulemans A., et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. J. Hepatol. 2016;64:609-617.
Not in our library10.1016/j.jhep.2015.11.011
84.
Takahashi S., Hasebe T., Oda T., Sasaki S., Kinoshita T., Konishi M., Ochiai T., Ochiai A. Cytoplasmic expression of laminin γ2 chain correlates with postoperative hepatic metastasis and poor prognosis in patients with pancreatic ductal adenocarcinoma. Cancer. 2002;94:1894-1901.
Not in our library10.1002/cncr.10395
85.
Shang M., Koshikawa N., Schenk S., Quaranta V. The LG3 module of laminin-5 harbors a binding site for integrin α3β1 that promotes cell adhesion, spreading, and migration. J. Biol. Chem. 2001;276:33045-33053.
Not in our library10.1074/jbc.m100798200
86.
Yao C.-C., Ziober B.L., Squillace R.M., Kramer R.H. α7 integrin mediates cell adhesion and migration on specific laminin isoforms. J. Biol. Chem. 1996;271:25598-25603.
Not in our library10.1074/jbc.271.41.25598
87.
Giannelli G., Azzariti A., Fransvea E., Porcelli L., Antonaci S., Paradiso A. Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells. Br. J. Cancer. 2004;91:1964-1969.
Not in our library10.1038/sj.bjc.6602231
88.
Tsurutani J., West K.A., Sayyah J., Gills J.J., Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res. 2005;65:8423-8432.
Not in our library10.1158/0008-5472.can-05-0058
89.
Pankov R., Yamada K.M. Fibronectin at a glance. J. Cell Sci. 2002;115:3861-3863.
Not in our library10.1242/jcs.00059
90.
Fibronectin-guided migration of carcinoma collectives · 2017
No notice
91.
Rintoul R.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. 2002;102:417-424.
Not in our library10.1042/cs20010216
92.
Hazlehurst L.A., Argilagos R.F., Emmons M., Boulware D., Beam C.A., Sullivan D.M., Dalton W.S. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006;66:2338-2345.
Not in our library10.1158/0008-5472.can-05-3256
93.
Kosmehl H., Berndt A., Strassburger S., Borsi L., Rousselle P., Mandel U., Hyckel P., Zardi L., Katenkamp D. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br. J. Cancer. 1999;81:1071-1079.
Not in our library10.1038/sj.bjc.6690809
94.
Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int. J. Cancer. 2006;118:1331-1339.
Not in our library10.1002/ijc.21677
95.
Liu W., Cheng S., Asa S.L., Ezzat S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 2008;68:8104-8112.
Not in our library10.1158/0008-5472.can-08-2132
96.
Bae Y.K., Kim A., Kim M.K., Choi J.E., Kang S.H., Lee S.J. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum. Pathol. 2013;44:2028-2037.
Not in our library10.1016/j.humpath.2013.03.006
97.
Hu D., Ansari D., Zhou Q., Sasor A., Said Hilmersson K., Andersson R. Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. World J. Surg. Oncol. 2019;17:1-8.
Not in our library10.1186/s12957-019-1574-z
98.
Singh P., Reimer C.L., Peters J.H., Stepp M.A., Hynes R.O., Van De Water L. The spatial and temporal expression patterns of integrin α9β1 and one of its ligands, the EIIIA segment of fibronectin, in cutaneous wound healing. J. Investig. Dermatol. 2004;123:1176-1181.
Not in our library10.1111/j.0022-202x.2004.23485.x
99.
Han S., Sidell N., Roser-Page S., Roman J. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int. J. Cancer. 2004;111:322-331.
Not in our library10.1002/ijc.20281
100.
Han S., Roman J. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: Pro-oncogenic effects mediated by PI3-kinase and NF-κB. Oncogene. 2006;25:4341-4349.
Not in our library10.1038/sj.onc.1209460
101.
Han S., Sidell N., Roman J. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk and Rho kinase. Cancer Lett. 2005;219:71-81.
Not in our library10.1016/j.canlet.2004.07.040
102.
Xing H., Weng D., Chen G., Tao W., Zhu T., Yang X., Meng L., Wang S., Lu Y., Ma D. Activation of fibronectin/PI-3K/Akt2 leads to chemoresistance to docetaxel by regulating survivin protein expression in ovarian and breast cancer cells. Cancer Lett. 2008;261:108-119.
Not in our library10.1016/j.canlet.2007.11.022
103.
Horiuchi K., Amizuka N., Takeshita S., Takamatsu H., Katsuura M., Ozawa H., Toyama Y., Bonewald L.F., Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 1999;14:1239-1249.
Not in our library10.1359/jbmr.1999.14.7.1239
104.
Moniuszko T., Wincewicz A., Koda M., Domysławska I., Sulkowski S. Role of periostin in esophageal, gastric and colon cancer. Oncol. Lett. 2016;12:783-787.
Not in our library10.3892/ol.2016.4692
105.
Gillan L., Matei D., Fishman D.A., Gerbin C.S., Karlan B.Y., Chang D.D. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358-5364.
Not in our library
106.
Cancer‐associated fibroblasts predict poor outcome and promote periostin‐dependent invasion in oesophageal adenocarcinoma · 2015
No notice
107.
Okazaki T., Tamai K., Shibuya R., Nakamura M., Mochizuki M., Yamaguchi K., Abe J., Takahashi S., Sato I., Kudo A. Periostin is a negative prognostic factor and promotes cancer cell proliferation in non-small cell lung cancer. Oncotarget. 2018;9:31187.
Not in our library10.18632/oncotarget.25435
108.
Zhu M., Fejzo M.S., Anderson L., Dering J., Ginther C., Ramos L., Gasson J.C., Karlan B.Y., Slamon D.J. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecol. Oncol. 2010;119:337-344.
Not in our library10.1016/j.ygyno.2010.07.008
109.
Tumbarello D.A., Temple J., Brenton J.D. ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells. Mol. Cancer. 2012;11:36.
Not in our library10.1186/1476-4598-11-36
110.
Sung P.-L., Jan Y.-H., Lin S.-C., Huang C.-C., Lin H., Wen K.-C., Chao K.-C., Lai C.-R., Wang P.-H., Chuang C.-M., et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget. 2016;7:4036-4047.
Not in our library10.18632/oncotarget.6700
111.
Liu Y., Du L. Role of pancreatic stellate cells and periostin in pancreatic cancer progression. Tumor Biol. 2015;36:3171-3177.
Not in our library10.1007/s13277-015-3386-2
112.
Tammi M.I., Day A.J., Turley E.A. Hyaluronan and homeostasis: A balancing act. J. Biol. Chem. 2002;277:4581-4584.
Not in our library10.1074/jbc.r100037200
113.
Hyaluronic Acid in the Third Millennium · 2018
No notice
114.
Kakehi K., Kinoshita M., Yasueda S.-i. Hyaluronic acid: Separation and biological implications. J. Chromatogr. B. 2003;797:347-355.
Not in our library10.1016/s1570-0232(03)00479-3
115.
Scott J.E. Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in the tissues. FASEB J. 1992;6:2639-2645.
Not in our library10.1096/fasebj.6.9.1612287
116.
Kupper S., Kłosowska-Chomiczewska I., Szumała P. Collagen and hyaluronic acid hydrogel in water-in-oil microemulsion delivery systems. Carbohydr. Polym. 2017;175:347-354.
Not in our library10.1016/j.carbpol.2017.08.010
117.
Pereira H., Sousa D.A., Cunha A., Andrade R., Espregueira-Mendes J., Oliveira J.M., Reis R.L. Hyaluronic acid. Advances in Experimental Medicine and Biology. 2018;137-153.
Not in our library10.1007/978-3-319-76735-2_6
118.
Henry C.B., Duling B.R. Permeation of the luminal capillary glycocalyx is determined by hyaluronan. Am. J. Physiol. Heart Circ. Physiol. 1999;277:H508-H514.
Not in our library10.1152/ajpheart.1999.277.2.h508
119.
Barbucci R., Lamponi S., Borzacchiello A., Ambrosio L., Fini M., Torricelli P., Giardino R. Hyaluronic acid hydrogel in the treatment of osteoarthritis. Biomaterials. 2002;23:4503-4513.
Not in our library10.1016/s0142-9612(02)00194-1
120.
Luo Y., Kirker K.R., Prestwich G.D. Cross-linked hyaluronic acid hydrogel films: New biomaterials for drug delivery. J. Control. Release. 2000;69:169-184.
Not in our library10.1016/s0168-3659(00)00300-x
121.
Bhattacharya D.S., Svechkarev D., Souchek J., Hill T.K., Taylor M., Natarajan A., Mohs A.M. Impact of structurally modifying hyaluronic acid on CD44 interaction. J. Mater. Chem. B. 2017;5:8183-8192.
Not in our library10.1039/c7tb01895a
122.
Necas J., Bartosikova L., Brauner P., Kolar J. Hyaluronic acid (hyaluronan): A review. Vet. Med. 2008;53:397-411.
Not in our library10.17221/1930-vetmed
123.
Brown N.H. Extracellular matrix in development: Insights from mechanisms conserved between invertebrates and vertebrates. Cold Spring. Harb. Perspect. Biol. 2011;3:a005082.
Not in our library10.1101/cshperspect.a005082
124.
Entchev E.V., González-Gaitán M.A. Morphogen gradient formation and vesicular trafficking. Traffic. 2002;3:98-109.
Not in our library10.1034/j.1600-0854.2002.030203.x
125.
Marois E., Mahmoud A., Eaton S. The endocytic pathway and formation of the Wingless morphogen gradient. Development. 2006;133:307-317.
Not in our library10.1242/dev.02197
126.
Uhler C., Shivashankar G.V. Regulation of genome organization and gene expression by nuclear mechanotransduction. Nat. Rev. Mol. Cell Biol. 2017;18:717-727.
Not in our library10.1038/nrm.2017.101
127.
Ilic D., Damsky C.H., Yamamoto T. Focal adhesion kinase: At the crossroads of signal transduction. J. Cell Sci. 1997;110:401-407.
Not in our library10.1242/jcs.110.4.401
128.
Kai F., Laklai H., Weaver V.M. Force Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease. Trends Cell Biol. 2016;26:486-497.
Not in our library10.1016/j.tcb.2016.03.007
129.
Rozario T., DeSimone D.W. The extracellular matrix in development and morphogenesis: A dynamic view. Dev. Biol. 2010;341:126-140.
Not in our library10.1016/j.ydbio.2009.10.026
130.
Park J., Kim D.-H., Levchenko A. Topotaxis: A new mechanism of directed cell migration in topographic ECM gradients. Biophys. J. 2018;114:1257-1263.
Not in our library10.1016/j.bpj.2017.11.3813
131.
Doyle A.D., Petrie R.J., Kutys M.L., Yamada K.M. Dimensions in cell migration. Curr. Opin. Cell Biol. 2013;25:642-649.
Not in our library10.1016/j.ceb.2013.06.004
132.
Gunawan R.C., Silvestre J., Gaskins H.R., Kenis P.J., Leckband D.E. Cell migration and polarity on microfabricated gradients of extracellular matrix proteins. Langmuir. 2006;22:4250-4258.
Not in our library10.1021/la0531493
133.
Wu J., Mao Z., Tan H., Han L., Ren T., Gao C. Gradient biomaterials and their influences on cell migration. Interface Focus. 2012;2:337-355.
Not in our library10.1098/rsfs.2011.0124
134.
Shellard A., Mayor R. All roads lead to directional cell migration. Trends Cell Biol. 2020;30:852-868.
Not in our library10.1016/j.tcb.2020.08.002
135.
Palecek S.P., Loftus J.C., Ginsberg M.H., Lauffenburger D.A., Horwitz A.F. Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 1997;385:537-540.
Not in our library10.1038/385537a0
136.
Hartman C.D., Isenberg B.C., Chua S.G., Wong J.Y. Extracellular matrix type modulates cell migration on mechanical gradients. Exp. Cell Res. 2017;359:361-366.
Not in our library10.1016/j.yexcr.2017.08.018
137.
Plotnikov S.V., Waterman C.M. Guiding cell migration by tugging. Curr. Opin. Cell Biol. 2013;25:619-626.
Not in our library10.1016/j.ceb.2013.06.003
138.
Pathak A., Kumar S. Independent regulation of tumor cell migration by matrix stiffness and confinement. Proc. Natl. Acad. Sci. USA. 2012;109:10334-10339.
Not in our library10.1073/pnas.1118073109
139.
Charras G., Sahai E. Physical influences of the extracellular environment on cell migration. Nat. Rev. Mol. Cell Biol. 2014;15:813-824.
Not in our library10.1038/nrm3897
140.
Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014;15:786-801.
Not in our library10.1038/nrm3904
141.
Rainero E. Extracellular matrix endocytosis in controlling matrix turnover and beyond: Emerging roles in cancer. Biochem. Soc. Trans. 2016;44:1347-1354.
Not in our library10.1042/bst20160159
142.
Hinck L., Silberstein G.B. Key stages in mammary gland development: The mammary end bud as a motile organ. Breast Cancer Res. 2005;7:245-251.
Not in our library10.1186/bcr1331
143.
Alford D., Baeckström D., Geyp M., Pitha P., Taylor-Papadimitriou J. Integrin-matrix interactions affect the form of the structures developing from human mammary epithelial cells in collagen or fibrin gels. J. Cell. Sci. 1998;111:521-532.
Not in our library10.1242/jcs.111.4.521
144.
Sakai T., Larsen M., Yamada K.M. Fibronectin requirement in branching morphogenesis. Nature. 2003;423:876-881.
Not in our library10.1038/nature01712
145.
Ortega N., Werb Z. New functional roles for non-collagenous domains of basement membrane collagens. J. Cell Sci. 2002;115:4201-4214.
Not in our library10.1242/jcs.00106
146.
Sternlicht M.D., Kouros-Mehr H., Lu P., Werb Z. Hormonal and local control of mammary branching morphogenesis. Differentiation. 2006;74:365-381.
Not in our library10.1111/j.1432-0436.2006.00105.x
147.
Yue B. Biology of the extracellular matrix: An overview. J. Glaucoma. 2014;23:S20.
Not in our library10.1097/ijg.0000000000000108
148.
The extracellular matrix in development · 2020
No notice
149.
Streuli C.H., Schmidhauser C., Bailey N., Yurchenco P., Skubitz A.P., Roskelley C., Bissell M.J. Laminin mediates tissue-specific gene expression in mammary epithelia. J. Cell Biol. 1995;129:591-603.
Not in our library10.1083/jcb.129.3.591
150.
Muncie J.M., Weaver V.M. The physical and biochemical properties of the extracellular matrix regulate cell fate. Curr. Top. Dev. Biol. 2018;130:1-37.
Not in our library10.1016/bs.ctdb.2018.02.002
151.
Gattazzo F., Urciuolo A., Bonaldo P. Extracellular matrix: A dynamic microenvironment for stem cell niche. Biochim. Biophys. Acta. 2014;1840:2506-2519.
Not in our library10.1016/j.bbagen.2014.01.010
152.
Dityatev A., Schachner M., Sonderegger P. The dual role of the extracellular matrix in synaptic plasticity and homeostasis. Nat. Rev. Neuroscience. 2010;11:735-746.
Not in our library10.1038/nrn2898
153.
Cox T.R., Erler J.T. Remodeling and homeostasis of the extracellular matrix: Implications for fibrotic diseases and cancer. Dis. Model. Mech. 2011;4:165-178.
Not in our library10.1242/dmm.004077
154.
Extracellular Matrix, a Hard Player in Angiogenesis · 2016
No notice
155.
Zhang D., Zhou C., Wang Q., Cai L., Du W., Li X., Zhou X., Xie J. Extracellular matrix elasticity regulates osteocyte gap junction elongation: Involvement of paxillin in intracellular signal transduction. Cell. Physiol. Biochem. 2018;51:1013-1026.
Not in our library10.1159/000495482
156.
Oh D.-J., Kang M.H., Ooi Y.H., Choi K.R., Sage E.H., Rhee D.J. Overexpression of SPARC in human trabecular meshwork increases intraocular pressure and alters extracellular matrix. Investig. Ophthalmol. Vis. Sci. 2013;54:3309-3319.
Not in our library10.1167/iovs.12-11362
157.
Terajima M., Taga Y., Cabral W.A., Liu Y., Nagasawa M., Sumida N., Kayashima Y., Chandrasekaran P., Han L., Maeda N. Cyclophilin B control of lysine post-translational modifications of skin type I collagen. PLoS Genet. 2019;15:e1008196.
Not in our library10.1371/journal.pgen.1008196
158.
Reynders M., Matsuura B.S., Bérouti M., Simoneschi D., Marzio A., Pagano M., Trauner D. PHOTACs enable optical control of protein degradation. Sci. Adv. 2020;6:eaay5064.
Not in our library10.1126/sciadv.aay5064
159.
Liu J., Chen H., Ma L., He Z., Wang D., Liu Y., Lin Q., Zhang T., Gray N., Kaniskan H.Ü. Light-induced control of protein destruction by opto-PROTAC. Sci. Adv. 2020;6:eaay5154.
Not in our library10.1126/sciadv.aay5154
160.
Ryan A., Liu J., Deiters A. Targeted protein degradation through fast optogenetic activation and its application to the control of cell signaling. J. Am. Chem. Soc. 2021;143:9222-9229.
Not in our library10.1021/jacs.1c04324
161.
Petrie R.J., Gavara N., Chadwick R.S., Yamada K.M. Nonpolarized signaling reveals two distinct modes of 3D cell migration. J. Cell Biol. 2012;197:439-455.
Not in our library10.1083/jcb.201201124
162.
Viji Babu P.K., Rianna C., Mirastschijski U., Radmacher M. Nano-mechanical mapping of interdependent cell and ECM mechanics by AFM force spectroscopy. Sci. Rep. 2019;9:1-19.
Not in our library10.1038/s41598-019-48566-7
163.
Maller O., Martinson H., Schedin P. Extracellular matrix composition reveals complex and dynamic stromal-epithelial interactions in the mammary gland. J. Mammary Gland Biol. Neoplasia. 2010;15:301-318.
Not in our library10.1007/s10911-010-9189-6
164.
Naba A., Clauser K.R., Hynes R.O. Enrichment of extracellular matrix proteins from tissues and digestion into peptides for mass spectrometry analysis. JoVE. 2015;101:e53057.
Not in our library10.3791/53057
165.
Robertson J., Humphries J.D., Paul N.R., Warwood S., Knight D., Byron A., Humphries M.J. Characterization of the phospho-adhesome by mass spectrometry-based proteomics. Kinase Signal. Netw. 2017;1636:235-251.
Not in our library10.1007/978-1-4939-7154-1_15
166.
De Castro Brás L.E., Ramirez T.A., DeLeon-Pennell K.Y., Chiao Y.A., Ma Y., Dai Q., Halade G.V., Hakala K., Weintraub S.T., Lindsey M.L. Texas 3-step decellularization protocol: Looking at the cardiac extracellular matrix. J. Proteom. 2013;86:43-52.
Not in our library10.1016/j.jprot.2013.05.004
167.
Herrera J.A., Mallikarjun V., Rosini S., Montero M.A., Lawless C., Warwood S., O’Cualain R., Knight D., Schwartz M.A., Swift J. Laser capture microdissection coupled mass spectrometry (LCM-MS) for spatially resolved analysis of formalin-fixed and stained human lung tissues. Clin. Proteom. 2020;17:1-12.
Not in our library10.1186/s12014-020-09287-6
168.
Coronado R.E., Somaraki-Cormier M., Natesan S., Christy R.J., Ong J.L., Halff G.A. Decellularization and solubilization of porcine liver for use as a substrate for porcine hepatocyte culture: Method optimization and comparison. Cell Transplant. 2017;26:1840-1854.
Not in our library10.1177/0963689717742157
169.
Alevra Sarika N., Payen V.L., Fléron M., Ravau J., Brusa D., Najimi M., De Pauw E., Eppe G., Mazzucchelli G., Sokal E.M. Human liver-derived extracellular matrix for the culture of distinct human primary liver cells. Cells. 2020;9:1357.
Not in our library10.3390/cells9061357
170.
Byron A., Humphries J.D., Humphries M.J. Defining the extracellular matrix using proteomics. Int. J. Exp. Pathol. 2013;94:75-92.
Not in our library10.1111/iep.12011
171.
Goddard E.T., Hill R.C., Barrett A., Betts C., Guo Q., Maller O., Borges V.F., Hansen K.C., Schedin P. Quantitative extracellular matrix proteomics to study mammary and liver tissue microenvironments. Int. J. Biochem. Cell Biol. 2016;81:223-232.
Not in our library10.1016/j.biocel.2016.10.014
172.
Krasny L., Bland P., Kogata N., Wai P., Howard B.A., Natrajan R.C., Huang P.H. SWATH mass spectrometry as a tool for quantitative profiling of the matrisome. J. Proteom. 2018;189:11-22.
Not in our library10.1016/j.jprot.2018.02.026
173.
Nguyen E.V., Pereira B.A., Lawrence M.G., Ma X., Rebello R.J., Chan H., Niranjan B., Wu Y., Ellem S., Guan X. Proteomic Profiling of Human Prostate Cancer-associated Fibroblasts (CAF) Reveals LOXL2-dependent Regulation of the Tumor Microenvironment*[S]. Mol. Cell. Proteom. 2019;18:1410-1427.
Not in our library10.1074/mcp.ra119.001496
174.
Zhou J.-Y., Schepmoes A.A., Zhang X., Moore R.J., Monroe M.E., Lee J.H., Camp D.G., Smith R.D., Qian W.-J. Improved LC− MS/MS spectral counting statistics by recovering low-scoring spectra matched to confidently identified peptide sequences. J. Proteome Res. 2010;9:5698-5704.
Not in our library10.1021/pr100508p
175.
Toghi Eshghi S., Shah P., Yang W., Li X., Zhang H. GPQuest: A spectral library matching algorithm for site-specific assignment of tandem mass spectra to intact N-glycopeptides. Anal. Chem. 2015;87:5181-5188.
Not in our library10.1021/acs.analchem.5b00024
176.
Wang M., Herrmann C.J., Simonovic M., Szklarczyk D., von Mering C. Version 4.0 of PaxDb: Protein abundance data, integrated across model organisms, tissues, and cell-lines. Proteomics. 2015;15:3163-3168.
Not in our library10.1002/pmic.201400441
177.
Roycik M.D., Fang X., Sang Q.X. A fresh prospect of extracellular matrix hydrolytic enzymes and their substrates. Curr. Pharm. Des. 2009;15:1295-1308.
Not in our library10.2174/138161209787846676
178.
Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. Matrix Biol. 2003;22:15-24.
Not in our library10.1016/s0945-053x(03)00006-4
179.
Roles of PLODs in Collagen Synthesis and Cancer Progression · 2018
No notice
180.
Gilkes D.M., Bajpai S., Wong C.C., Chaturvedi P., Hubbi M.E., Wirtz D., Semenza G.L. Procollagen Lysyl Hydroxylase 2 Is Essential for Hypoxia-Induced Breast Cancer MetastasisPLOD2 Is Essential for Hypoxia-Induced Metastasis. Mol. Cancer Res. 2013;11:456-466.
Not in our library10.1158/1541-7786.mcr-12-0629
181.
Eddy A.A. Molecular basis of renal fibrosis. Pediatr. Nephrol. 2000;15:290-301.
Not in our library10.1007/s004670000461
182.
Alcolado R., Arthur M., Iredale J. Pathogenesis of liver fibrosis. Clin. Sci. 1997;92:103-112.
Not in our library10.1042/cs0920103
183.
Libring S., Shinde A., Chanda M.K., Nuru M., George H., Saleh A.M., Abdullah A., Kinzer-Ursem T.L., Calve S., Wendt M.K. The dynamic relationship of breast cancer cells and fibroblasts in fibronectin accumulation at primary and metastatic tumor sites. Cancers. 2020;12:1270.
Not in our library10.3390/cancers12051270
184.
Comoglio P.M., Trusolino L. Cancer: The matrix is now in control. Nat. Med. 2005;11:1156-1158.
Not in our library10.1038/nm1105-1156
185.
Pires A., Greenshields-Watson A., Jones E., Smart K., Lauder S.N., Somerville M., Milutinovic S., Kendrick H., Hindley J.P., French R., et al. Immune Remodeling of the Extracellular Matrix Drives Loss of Cancer Stem Cells and Tumor Rejection. Cancer Immunol. Res. 2020;8:1520-1531.
Not in our library10.1158/2326-6066.cir-20-0070
186.
Kessenbrock K., Wang C.Y., Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 2015;44-46:184-190.
Not in our library10.1016/j.matbio.2015.01.022
187.
Fonović M., Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim. Biophys. Acta. 2014;1840:2560-2570.
Not in our library10.1016/j.bbagen.2014.03.017
188.
Cox T.R., Erler J.T. Fibrosis and Cancer: Partners in Crime or Opposing Forces? Trends Cancer. 2016;2:279-282.
Not in our library10.1016/j.trecan.2016.05.004
189.
Filipe E.C., Chitty J.L., Cox T.R. Charting the unexplored extracellular matrix in cancer. Int. J. Exp. Pathol. 2018;99:58-76.
Not in our library10.1111/iep.12269
190.
Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009;139:891-906.
Not in our library10.1016/j.cell.2009.10.027
191.
Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment · 2021
No notice
192.
Kench J.A., Russell D.M., Fadok V.A., Young S.K., Worthen G.S., Jones-Carson J., Henson J.E., Henson P.M., Nemazee D. Aberrant wound healing and TGF-β production in the autoimmune-prone MRL/+ mouse. Clin. Immunol. 1999;92:300-310.
Not in our library10.1006/clim.1999.4754
193.
Zhao Y., Bao L., Chan L.S., DiPietro L.A., Chen L. Aberrant wound healing in an epidermal interleukin-4 transgenic mouse model of atopic dermatitis. PLoS ONE. 2016;11:e0146451.
Not in our library10.1371/journal.pone.0146451
194.
Hertle M.D., Kubler M.-D., Leigh I.M., Watt F. Aberrant integrin expression during epidermal wound healing and in psoriatic epidermis. J. Clin. Investig. 1992;89:1892-1901.
Not in our library10.1172/jci115794
195.
Stephens P., Grenard P., Aeschlimann P., Langley M., Blain E., Errington R., Kipling D., Thomas D., Aeschlimann D. Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J. Cell Sci. 2004;117:3389-3403.
Not in our library10.1242/jcs.01188
196.
Chitty J.L., Setargew Y.F.I., Cox T.R. Targeting the lysyl oxidases in tumour desmoplasia. Biochem. Soc. Trans. 2019;47:1661-1678.
Not in our library10.1042/bst20190098
197.
Ponce I., Garrido N., Tobar N., Melo F., Smith P.C., Martínez J. Matrix stiffness modulates metabolic interaction between human stromal and breast cancer cells to stimulate epithelial motility. Metabolites. 2021;11:432.
Not in our library10.3390/metabo11070432
198.
DuFort C.C., DelGiorno K.E., Hingorani S.R. Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2016;150:1545-1557.e2.
Not in our library10.1053/j.gastro.2016.03.040
199.
Scarpellini A., Germack R., Lortat-Jacob H., Muramatsu T., Billett E., Johnson T., Verderio E.A. Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of transglutaminase-2. J. Biol. Chem. 2009;284:18411-18423.
Not in our library10.1074/jbc.m109.012948
200.
Cardoso I., Stamnaes J., Andersen J.T., Melino G., Iversen R., Sollid L.M. Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies. FEBS J. 2015;282:2063-2075.
Not in our library10.1111/febs.13276
201.
Akimov S.S., Krylov D., Fleischman L.F., Belkin A.M. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J. Cell Biol. 2000;148:825-838.
Not in our library10.1083/jcb.148.4.825
202.
Richter P., Junker K., Franz M., Berndt A., Geyer C., Gajda M., Kosmehl H., Berndt A., Wunderlich H. IIICS de novo glycosylated fibronectin as a marker for invasiveness in urothelial carcinoma of the urinary bladder (UBC). J. Cancer Res. Clin. Oncol. 2008;134:1059-1065.
Not in our library10.1007/s00432-008-0390-6
203.
Freire-de-Lima L., Gelfenbeyn K., Ding Y., Mandel U., Clausen H., Handa K., Hakomori S.-i. Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc. Natl. Acad. Sci. USA. 2011;108:17690-17695.
Not in our library10.1073/pnas.1115191108
204.
SUZUkI O., Abe M., Hashimoto Y. Sialylation and glycosylation modulate cell adhesion and invasion to extracellular matrix in human malignant lymphoma: Dependency on integrin and the Rho GTPase family. Int. J. Oncol. 2015;47:2091-2099.
Not in our library10.3892/ijo.2015.3211
205.
Singh C., Shyanti R.K., Singh V., Kale R.K., Mishra J.P., Singh R.P. Integrin expression and glycosylation patterns regulate cell-matrix adhesion and alter with breast cancer progression. Biochem. Biophys. Res. Commun. 2018;499:374-380.
Not in our library10.1016/j.bbrc.2018.03.169
206.
Rathinam R., Alahari S.K. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29:223-237.
Not in our library10.1007/s10555-010-9211-x
207.
Yalak G., Vogel V. Ectokinases as novel cancer markers and drug targets in cancer therapy. Cancer Med. 2015;4:404-414.
Not in our library10.1002/cam4.368
208.
Yalak G., Shiu J.-Y., Schoen I., Mitsi M., Vogel V. Phosphorylated fibronectin enhances cell attachment and upregulates mechanical cell functions. PLoS ONE. 2019;14:e0218893.
Not in our library10.1371/journal.pone.0218893
209.
Wolanska K.I., Morgan M.R. Fibronectin remodelling: Cell-mediated regulation of the microenvironment. Biochem. Soc. Trans. 2015;43:122-128.
Not in our library10.1042/bst20140313
210.
Soares Da Costa D., Reis R.L., Pashkuleva I. Sulfation of glycosaminoglycans and its implications in human health and disorders. Annu. Rev. Biomed. Eng. 2017;19:1-26.
Not in our library10.1146/annurev-bioeng-071516-044610
211.
Escobar Galvis M.L., Jia J., Zhang X., Jastrebova N., Spillmann D., Gottfridsson E., Van Kuppevelt T.H., Zcharia E., Vlodavsky I., Lindahl U. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate. Nat. Chem. Biol. 2007;3:773-778.
Not in our library10.1038/nchembio.2007.41
212.
Vlodavsky I., Gross-Cohen M., Weissmann M., Ilan N., Sanderson R.D. Opposing functions of heparanase-1 and heparanase-2 in cancer progression. Trends Biochem. Sci. 2018;43:18-31.
Not in our library10.1016/j.tibs.2017.10.007
213.
Humphrey J.D., Dufresne E.R., Schwartz M.A. Mechanotransduction and extracellular matrix homeostasis. Nat. Rev. Mol. Cell Biol. 2014;15:802-812.
Not in our library10.1038/nrm3896
214.
Hamacher S., Matern S., Roeb E. Extracellular matrix—From basic research to clinical significance. An overview with special consideration of matrix metalloproteinases. Dtsch. Med. Wochenschr. 2004;129:1976-1980.
Not in our library10.1055/s-2004-831836
215.
Toth M., Fridman R. Assessment of gelatinases (MMP-2 and MMP-9 by gelatin zymography. Metastasis Research Protocols. 2001;Volume 57:163-174.
Not in our library10.1385/1-59259-136-1:163
216.
Zhou Z., Liu Y., Gao S., Zhou M., Qi F., Ding N., Zhang J., Li R., Wang J., Shi J. Excessive DNA damage mediates ECM degradation via the RBBP8/NOTCH1 pathway in sporadic aortic dissection. Biochim. Biophys. Acta Mol. Basis Dis. 2022;1868:166303.
Not in our library10.1016/j.bbadis.2021.166303
217.
Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011;3:a005058.
Not in our library10.1101/cshperspect.a005058
218.
Stetler-Stevenson W.G., Liotta L.A., Kleiner D.E. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
Not in our library10.1096/fasebj.7.15.8262328
219.
Yuzhalin A.E., Lim S.Y., Kutikhin A.G., Gordon-Weeks A.N. Dynamic matrisome: ECM remodeling factors licensing cancer progression and metastasis. Biochim. Biophys. Acta Rev. Cancer. 2018;1870:207-228.
Not in our library10.1016/j.bbcan.2018.09.002
220.
Chow A., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br. J. Pharmacol. 2007;152:189-205.
Not in our library10.1038/sj.bjp.0707344
221.
Mott J.D., Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr. Opin. Cell Biol. 2004;16:558-564.
Not in our library10.1016/j.ceb.2004.07.010
222.
Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000;2:737-744.
Not in our library10.1038/35036374
223.
Siqueira A.S., Carvalho M.R., Monteiro A.C., Freitas V.M., Jaeger R.G., Pinheiro J.J. Matrix metalloproteinases, TIMPs and growth factors regulating ameloblastoma behaviour. Histopathology. 2010;57:128-137.
Not in our library10.1111/j.1365-2559.2010.03596.x
224.
Rodríguez D., Morrison C.J., Overall C.M. Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta Mol. Cell Res. 2010;1803:39-54.
Not in our library10.1016/j.bbamcr.2009.09.015
225.
Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006;69:562-573.
Not in our library10.1016/j.cardiores.2005.12.002
226.
Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 2010;141:52-67.
Not in our library10.1016/j.cell.2010.03.015
227.
Shimoda M., Ohtsuka T., Okada Y., Kanai Y. Stromal metalloproteinases: Crucial contributors to the tumor microenvironment. Pathol. Int. 2021;71:1-14.
Not in our library10.1111/pin.13033
228.
Concepts of extracellular matrix remodelling in tumour progression and metastasis · 2020
No notice
229.
Mittal R., Patel A.P., Debs L.H., Nguyen D., Patel K., Grati M.h., Mittal J., Yan D., Chapagain P., Liu X.Z. Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J. Cell. Physiol. 2016;231:2599-2621.
Not in our library10.1002/jcp.25430
230.
Jacob M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed. Pharmacother. 2003;57:195-202.
Not in our library10.1016/s0753-3322(03)00065-9
231.
Stadlmann S., Pollheimer J., Moser P.L., Raggi A., Amberger A., Margreiter R., Offner F.A., Mikuz G., Dirnhofer S., Moch H. Cytokine-regulated expression of collagenase-2 (MMP-8) is involved in the progression of ovarian cancer. Eur. J. Cancer. 2003;39:2499-2505.
Not in our library10.1016/j.ejca.2003.08.011
232.
Åström P., Juurikka K., Hadler-Olsen E.S., Svineng G., Cervigne N.K., Coletta R.D., Risteli J., Kauppila J.H., Skarp S., Kuttner S., et al. The interplay of matrix metalloproteinase-8, transforming growth factor-β1 and vascular endothelial growth factor-C cooperatively contributes to the aggressiveness of oral tongue squamous cell carcinoma. Br. J. Cancer. 2017;117:1007-1016.
Not in our library10.1038/bjc.2017.249
233.
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics · 2020
No notice
234.
Markland F.S. Snake venoms and the hemostatic system. Toxicon. 1998;36:1749-1800.
Not in our library10.1016/s0041-0101(98)00126-3
235.
Rossello A., Nuti E., Ferrini S., Fabbi M. Targeting ADAM17 Sheddase Activity in Cancer. Curr. Drug. Targets. 2016;17:1908-1927.
Not in our library10.2174/1389450117666160727143618
236.
Van Goor H., Melenhorst W.B., Turner A.J., Holgate S.T. Adamalysins in biology and disease. J. Pathol. A J. Pathol. Soc. Great Br. Irel. 2009;219:277-286.
Not in our library10.1002/path.2594
237.
Killar L., White J., Black R., Peschon J. Adamalysins: A family of metzincins including TNF-α converting enzyme (TACE). Ann. N. Y. Acad. Sci. 1999;878:442-452.
Not in our library10.1111/j.1749-6632.1999.tb07701.x
238.
Turk V., Stoka V., Vasiljeva O., Renko M., Sun T., Turk B., Turk D. Cysteine cathepsins: From structure, function and regulation to new frontiers. Biochim. Biophys. Acta Proteins Proteom. 2012;1824:68-88.
Not in our library10.1016/j.bbapap.2011.10.002
239.
Conus S. Cathepsins and their involvement in immune responses. Swiss Med. Wkly. 2010;140:w13042.
Not in our library10.4414/smw.2010.13042
240.
The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management · 2020
No notice
241.
Ishidoh K., Kominami E. Procathepsin L degrades extracellular matrix proteins in the presence of glycosaminoglycans in vitro. Biochem. Biophys. Res. Commun. 1995;217:624-631.
Not in our library10.1006/bbrc.1995.2820
242.
Taleb S., Cancello R., Clément K., Lacasa D. Cathepsin s promotes human preadipocyte differentiation: Possible involvement of fibronectin degradation. Endocrinology. 2006;147:4950-4959.
Not in our library10.1210/en.2006-0386
243.
Nomura T., Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J. Med. Investig. 2005;52:1-9.
Not in our library10.2152/jmi.52.1
244.
Tan G.-J., Peng Z.-K., Lu J.-P., Tang F.-Q. Cathepsins mediate tumor metastasis. World J. Biol. Chem. 2013;4:91.
Not in our library10.4331/wjbc.v4.i4.91
245.
Rudzińska M., Parodi A., Soond S.M., Vinarov A.Z., Korolev D.O., Morozov A.O., Daglioglu C., Tutar Y., Zamyatnin A.A. The role of cysteine cathepsins in cancer progression and drug resistance. Int. J. Mol. Sci. 2019;20:3602.
Not in our library10.3390/ijms20143602
246.
Llorens F., Thüne K., Sikorska B., Schmitz M., Tahir W., Fernández-Borges N., Cramm M., Gotzmann N., Carmona M., Streichenberger N. Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease. Acta Neuropathol. Commun. 2017;5:1-20.
Not in our library10.1186/s40478-017-0431-y
247.
Büth H., Buttigieg P.L., Ostafe R., Rehders M., Dannenmann S.R., Schaschke N., Stark H.-J., Boukamp P., Brix K. Cathepsin B is essential for regeneration of scratch-wounded normal human epidermal keratinocytes. Eur. J. Cell Biol. 2007;86:747-761.
Not in our library10.1016/j.ejcb.2007.03.009
248.
Hopkins D.R., Keles S., Greenspan D.S. The bone morphogenetic protein 1/Tolloid-like metalloproteinases. Matrix Biol. 2007;26:508-523.
Not in our library10.1016/j.matbio.2007.05.004
249.
Steiglitz B.M., Ayala M., Narayanan K., George A., Greenspan D.S. Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1. J. Biol. Chem. 2004;279:980-986.
Not in our library10.1074/jbc.m310179200
250.
Vadon-Le Goff S., Hulmes D.J., Moali C. BMP-1/tolloid-like proteinases synchronize matrix assembly with growth factor activation to promote morphogenesis and tissue remodeling. Matrix Biol. 2015;44-46:14-23.
Not in our library10.1016/j.matbio.2015.02.006
251.
Ge G., Greenspan D.S. Developmental roles of the BMP1/TLD metalloproteinases. Birth Defects Res. C Embryo Today. 2006;78:47-68.
Not in our library10.1002/bdrc.20060
252.
Malecaze F., Massoudi D., Fournié P., Tricoire C., Cassagne M., Malbouyres M., Hulmes D.J., Moali C., Galiacy S.D. Upregulation of bone morphogenetic protein-1/mammalian tolloid and procollagen C-proteinase enhancer-1 in corneal scarring. Investig. Ophthalmol. Vis. Sci. 2014;55:6712-6721.
Not in our library10.1167/iovs.13-13800
253.
Muir A.M., Massoudi D., Nguyen N., Keene D.R., Lee S.-J., Birk D.E., Davidson J.M., Marinkovich M.P., Greenspan D.S. BMP1-like proteinases are essential to the structure and wound healing of skin. Matrix Biol. 2016;56:114-131.
Not in our library10.1016/j.matbio.2016.06.004
254.
Stern R. Hyaluronidases in cancer biology. Semin Cancer Biol. 2008;18:275-280.
Not in our library10.1016/j.semcancer.2008.03.017
255.
Dissecting the Dual Nature of Hyaluronan in the Tumor Microenvironment · 2019
No notice
256.
Yamaguchi Y., Yamamoto H., Tobisawa Y., Irie F. TMEM2: A missing link in hyaluronan catabolism identified? Matrix Biol. 2019;78-79:139-146.
Not in our library10.1016/j.matbio.2018.03.020
257.
Tammi M.I., Oikari S., Pasonen-Seppänen S., Rilla K., Auvinen P., Tammi R.H. Activated hyaluronan metabolism in the tumor matrix—Causes and consequences. Matrix Biol. 2019;78–79:147-164.
Not in our library10.1016/j.matbio.2018.04.012
258.
Stern R. Hyaluronan metabolism: A major paradox in cancer biology. Pathol. Biol. 2005;53:372-382.
Not in our library10.1016/j.patbio.2004.12.021
259.
Girish K., Kemparaju K. The magic glue hyaluronan and its eraser hyaluronidase: A biological overview. Life Sci. 2007;80:1921-1943.
Not in our library10.1016/j.lfs.2007.02.037
260.
Stern R., Asari A.A., Sugahara K.N. Hyaluronan fragments: An information-rich system. Eur. J. Cell Biol. 2006;85:699-715.
Not in our library10.1016/j.ejcb.2006.05.009
261.
Jiang D., Liang J., Noble P.W. Hyaluronan in Tissue Injury and Repair. Annu. Rev. Cell Dev. Biol. 2007;23:435-461.
Not in our library10.1146/annurev.cellbio.23.090506.123337
262.
Hyaluronan: Metabolism and Function · 2020
No notice
263.
Jiang D., Liang J., Noble P.W. Hyaluronan as an immune regulator in human diseases. Physiol. Rev. 2011;91:221-264.
Not in our library10.1152/physrev.00052.2009
264.
Noble P.W. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol. 2002;21:25-29.
Not in our library10.1016/s0945-053x(01)00184-6
265.
Heldin P., Basu K., Olofsson B., Porsch H., Kozlova I., Kahata K. Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J. Biochem. 2013;154:395-408.
Not in our library10.1093/jb/mvt085
266.
Bame K.J. Heparanases: Endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 2001;11:91R-98R.
Not in our library10.1093/glycob/11.6.91r
267.
Zcharia E., Zilka R., Yaar A., Yacoby-Zeevi O., Zetser A., Metzger S., Sarid R., Naggi A., Casu B., Ilan N. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 2005;19:211-221.
Not in our library10.1096/fj.04-1970com
268.
Crispel Y., Ghanem S., Attias J., Kogan I., Brenner B., Nadir Y. Involvement of the heparanase procoagulant domain in bleeding and wound healing. J. Thromb. Haemost. 2017;15:1463-1472.
Not in our library10.1111/jth.13707
269.
Sanderson R.D., Elkin M., Rapraeger A.C., Ilan N., Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: New mechanisms and targets for therapy. FEBS J. 2017;284:42-55.
Not in our library10.1111/febs.13932
270.
Khanna M., Parish C.R. Heparanase: Historical Aspects and Future Perspectives. Adv. Exp. Med. Biol. 2020;1221:71-96.
Not in our library10.1007/978-3-030-34521-1_3
271.
Itoh Y. Membrane-type matrix metalloproteinases: Their functions and regulations. Matrix Biol. 2015;44:207-223.
Not in our library10.1016/j.matbio.2015.03.004
272.
Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003;92:827-839.
Not in our library10.1161/01.res.0000070112.80711.3d
273.
Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim. Biophys. Acta Mol. Cell Res. 2010;1803:55-71.
Not in our library10.1016/j.bbamcr.2010.01.003
274.
Baker E.A., Leaper D.J. Profiles of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: Relationship to wound healing. Wound Repair Regen. 2003;11:268-274.
Not in our library10.1046/j.1524-475x.2003.11406.x
275.
Xue M., Jackson C.J. Extracellular Matrix Reorganization During Wound Healing and Its Impact on Abnormal Scarring. Adv. Wound Care. 2015;4:119-136.
Not in our library10.1089/wound.2013.0485
276.
Breznik B., Mitrović A., Lah T.T., Kos J. Cystatins in cancer progression: More than just cathepsin inhibitors. Biochimie. 2019;166:233-250.
Not in our library10.1016/j.biochi.2019.05.002
277.
Van Gent D., Sharp P., Morgan K., Kalsheker N. Serpins: Structure, function and molecular evolution. Int. J. Biochem. Cell Biol. 2003;35:1536-1547.
Not in our library10.1016/s1357-2725(03)00134-1
278.
Rau J., Beaulieu L., Huntington J., CHURCH F.C. Serpins in thrombosis, hemostasis and fibrinolysis. J. Thromb. Haemost. 2007;5:102-115.
Not in our library10.1111/j.1538-7836.2007.02516.x
279.
Carrell R.W., Evans D.L., Stein P.E. Mobile reactive centre of serpins and the control of thrombosis. Nature. 1991;353:576-578.
Not in our library10.1038/353576a0
280.
Sorokin L. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 2010;10:712-723.
Not in our library10.1038/nri2852
281.
Ricard-Blum S., Vallet S.D. Proteases decode the extracellular matrix cryptome. Biochimie. 2016;122:300-313.
Not in our library10.1016/j.biochi.2015.09.016
282.
Lee J.H., Isayeva T., Larson M.R., Sawant A., Cha H.R., Chanda D., Chesnokov I.N., Ponnazhagan S. Endostatin: A novel inhibitor of androgen receptor function in prostate cancer. Proc. Natl. Acad. Sci. USA. 2015;112:1392-1397.
Not in our library10.1073/pnas.1417660112
283.
Magnon C., Galaup A., Mullan B., Rouffiac V., Bouquet C., Bidart J.M., Griscelli F., Opolon P., Perricaudet M. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 2005;65:4353-4361.
Not in our library10.1158/0008-5472.can-04-3536
284.
Wang S., Lu X.A., Liu P., Fu Y., Jia L., Zhan S., Luo Y. Endostatin has ATPase activity, which mediates its antiangiogenic and antitumor activities. Mol. Cancer. 2015;14:1192-1201.
Not in our library10.1158/1535-7163.mct-14-0836
285.
Colorado P.C., Torre A., Kamphaus G., Maeshima Y., Hopfer H., Takahashi K., Volk R., Zamborsky E.D., Herman S., Sarkar P.K., et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 2000;60:2520-2526.
Not in our library
286.
Albrengues J., Shields M.A., Ng D., Park C.G., Ambrico A., Poindexter M.E., Upadhyay P., Uyeminami D.L., Pommier A., Küttner V., et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361:eaao4227.
Not in our library10.1126/science.aao4227
287.
Chandler C., Liu T., Buckanovich R., Coffman L.G. The double edge sword of fibrosis in cancer. Transl. Res. 2019;209:55-67.
Not in our library10.1016/j.trsl.2019.02.006
288.
Extracellular Matrix and Cytokines: A Functional Unit · 2000
No notice
289.
Foster D.S., Jones R.E., Ransom R.C., Longaker M.T., Norton J.A. The evolving relationship of wound healing and tumor stroma. JCI Insight. 2018;3:e99911.
Not in our library10.1172/jci.insight.99911
290.
Dvorak H.F. Tumors: Wounds that do not heal—A historical perspective with a focus on the fundamental roles of increased vascular permeability and clotting. Proceedings of the Seminars in Thrombosis and Hemostasis. 2019;576-592.
Not in our library10.1055/s-0039-1687908
291.
Dzobo K., Dandara C. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. Omics. 2020;24:314-339.
Not in our library10.1089/omi.2020.0023
292.
Dzobo K., Dandara C. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes. Omics. 2020;24:340-351.
Not in our library10.1089/omi.2020.0042
293.
Bochet L., Lehuédé C., Dauvillier S., Wang Y.Y., Dirat B., Laurent V., Dray C., Guiet R., Maridonneau-Parini I., Le Gonidec S., et al. Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer. Cancer Res. 2013;73:5657-5668.
Not in our library10.1158/0008-5472.can-13-0530
294.
Mu W., Rana S., Zöller M. Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 2013;15:875-887.
Not in our library10.1593/neo.13786
295.
Webber J.P., Spary L.K., Sanders A.J., Chowdhury R., Jiang W.G., Steadman R., Wymant J., Jones A.T., Kynaston H., Mason M.D., et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 2015;34:290-302.
Not in our library10.1038/onc.2013.560
296.
Stromal Myofibroblasts Are Associated with Poor Prognosis in Solid Cancers: A Meta-Analysis of Published Studies. · 2016
Not checked
297.
Yamashita M., Ogawa T., Zhang X., Hanamura N., Kashikura Y., Takamura M., Yoneda M., Shiraishi T. Role of stromal myofibroblasts in invasive breast cancer: Stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome. Breast Cancer. 2012;19:170-176.
Not in our library10.1007/s12282-010-0234-5
298.
Tsujino T., Seshimo I., Yamamoto H., Ngan C.Y., Ezumi K., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., Monden M. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 2007;13:2082-2090.
Not in our library10.1158/1078-0432.ccr-06-2191
299.
Fibroblast-mediated uncaging of cancer cells and dynamic evolution of the physical microenvironment · 2022
Not checked
300.
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer · 2017
No notice
301.
Elyada E., Bolisetty M., Laise P., Flynn W.F., Courtois E.T., Burkhart R.A., Teinor J.A., Belleau P., Biffi G., Lucito M.S., et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9:1102-1123.
Not in our library10.1158/2159-8290.cd-19-0094
302.
Tian C., Öhlund D., Rickelt S., Lidström T., Huang Y., Hao L., Zhao R.T., Franklin O., Bhatia S.N., Tuveson D.A., et al. Cancer Cell–Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2020;80:1461-1474.
Not in our library10.1158/0008-5472.can-19-2578
303.
Lim S.B., Chua M.L.K., Yeong J.P.S., Tan S.J., Lim W.-T., Lim C.T. Pan-cancer analysis connects tumor matrisome to immune response. NPJ Precis. Oncol. 2019;3:1-9.
Not in our library10.1038/s41698-019-0087-0
304.
Rafaeva M., Erler J.T. Framing cancer progression: Influence of the organ-and tumour-specific matrisome. FEBS J. 2020;287:1454-1477.
Not in our library10.1111/febs.15223
305.
Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination · 2016
No notice
306.
Tacconi C., Correale C., Gandelli A., Spinelli A., Dejana E., D’Alessio S., Danese S. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion. Gastroenterology. 2015;148:1438-1451.e8.
Not in our library10.1053/j.gastro.2015.03.005
307.
Le C.P., Karnezis T., Achen M.G., Stacker S.A., Sloan E.K. Lymphovascular and neural regulation of metastasis: Shared tumour signalling pathways and novel therapeutic approaches. Best Pract. Res. Clin. Anaesthesiol. 2013;27:409-425.
Not in our library10.1016/j.bpa.2013.10.008
308.
Nagaraja A.S., Dood R.L., Armaiz-Pena G., Kang Y., Wu S.Y., Allen J.K., Jennings N.B., Mangala L.S., Pradeep S., Lyons Y., et al. Adrenergic-mediated increases in INHBA drive CAF phenotype and collagens. JCI Insight. 2017;2:e93076.
Not in our library10.1172/jci.insight.93076
309.
Insua-Rodríguez J., Pein M., Hongu T., Meier J., Descot A., Lowy C.M., De Braekeleer E., Sinn H.P., Spaich S., Sütterlin M., et al. Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis. EMBO Mol. Med. 2018;10:e9003.
Not in our library10.15252/emmm.201809003
310.
Afasizheva A., Devine A., Tillman H., Fung K.L., Vieira W.D., Blehm B.H., Kotobuki Y., Busby B., Chen E.I., Tanner K. Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival. BMC Cancer. 2016;16:186.
Not in our library10.1186/s12885-016-2211-7
311.
Steins A., van Mackelenbergh M.G., van der Zalm A.P., Klaassen R., Serrels B., Goris S.G., Kocher H.M., Waasdorp C., de Jong J.H., Tekin C., et al. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. EMBO Rep. 2020;21:e48780.
Not in our library10.15252/embr.201948780
312.
Vera R.E., Fernandez-Zapico M.E. Stromal deactivation by CSF1: A new feature of the aggressive pancreatic cancer microenvironment. EMBO Rep. 2020;21:e50468.
Not in our library10.15252/embr.202050468
313.
The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma · 2018
No notice
314.
Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer · 2018
Corrected
315.
Palumbo Jr A., Ferreira L.B., de Souza P.A.R., de Oliveira F.L., Pontes B., Viana N.B., Machado D.E., Palmero C.Y., Alves L.M., Gimba E.R. Extracellular matrix secreted by reactive stroma is a main inducer of pro-tumorigenic features on LNCaP prostate cancer cells. Cancer Lett. 2012;321:55-64.
Not in our library10.1016/j.canlet.2012.02.026
316.
Barcus C.E., Holt E.C., Keely P.J., Eliceiri K.W., Schuler L.A. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS ONE. 2015;10:e0116891.
Not in our library10.1371/journal.pone.0116891
317.
Brown Y., Hua S., Tanwar P.S. Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. Int. J. Biochem. Cell Biol. 2019;109:90-104.
Not in our library10.1016/j.biocel.2019.02.002
318.
Chemoresistance and the Self-Maintaining Tumor Microenvironment · 2018
No notice
319.
Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance · 2021
No notice
320.
Keeratichamroen S., Lirdprapamongkol K., Svasti J. Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. Oncol. Rep. 2018;39:1765-1774.
Not in our library10.3892/or.2018.6258
321.
Mocanu M.M., Fazekas Z., Petrás M., Nagy P., Sebestyén Z., Isola J., Tímár J., Park J.W., Vereb G., Szöllosi J. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett. 2005;227:201-212.
Not in our library10.1016/j.canlet.2005.01.028
322.
Guo W., Pylayeva Y., Pepe A., Yoshioka T., Muller W.J., Inghirami G., Giancotti F.G. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006;126:489-502.
Not in our library10.1016/j.cell.2006.05.047
323.
Nguyen T.V., Sleiman M., Moriarty T., Herrick W.G., Peyton S.R. Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening. Biomaterials. 2014;35:5749-5759.
Not in our library10.1016/j.biomaterials.2014.03.058
324.
Keely P.J. Mechanisms by which the extracellular matrix and integrin signaling act to regulate the switch between tumor suppression and tumor promotion. J. Mammary Gland Biol. Neoplasia. 2011;16:205-219.
Not in our library10.1007/s10911-011-9226-0
325.
Weigelt B., Lo A.T., Park C.C., Gray J.W., Bissell M.J. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res. Treat. 2010;122:35-43.
Not in our library10.1007/s10549-009-0502-2
326.
Dzobo K. Integrins Within the Tumor Microenvironment: Biological Functions, Importance for Molecular Targeting, and Cancer Therapeutics Innovation. Omics. 2021;25:417-430.
Not in our library10.1089/omi.2021.0069
327.
Guerrero P.A., McCarty J.H. Integrins in Vascular Development and Pathology. Adv. Pharm. 2018;81:129-153.
Not in our library10.1016/bs.apha.2017.08.011
328.
Conway J.R.W., Jacquemet G. Cell matrix adhesion in cell migration. Essays Biochem. 2019;63:535-551.
Not in our library10.1042/ebc20190012
329.
Zhang Y., Reif G., Wallace D.P. Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease. Cell Signal. 2020;72:109646.
Not in our library10.1016/j.cellsig.2020.109646
330.
Hamidi H., Ivaska J. Every step of the way: Integrins in cancer progression and metastasis. Nat. Rev. Cancer. 2018;18:533-548.
Not in our library10.1038/s41568-018-0038-z
331.
Samaržija I., Dekanić A., Humphries J.D., Paradžik M., Stojanović N., Humphries M.J., Ambriović-Ristov A. Integrin crosstalk contributes to the complexity of signalling and unpredictable cancer cell fates. Cancers. 2020;12:1910.
Not in our library10.3390/cancers12071910
332.
Varner J.A., Emerson D.A., Juliano R.L. Integrin alpha 5 beta 1 expression negatively regulates cell growth: Reversal by attachment to fibronectin. Mol. Biol. Cell. 1995;6:725-740.
Not in our library10.1091/mbc.6.6.725
333.
Stoeltzing O., Liu W., Reinmuth N., Fan F., Parry G.C., Parikh A.A., McCarty M.F., Bucana C.D., Mazar A.P., Ellis L.M. Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer. 2003;104:496-503.
Not in our library10.1002/ijc.10958
334.
Integrins: roles in cancer development and as treatment targets · 2004
No notice
335.
Varner J.A., Cheresh D.A. Integrins and cancer. Curr. Opin. Cell Biol. 1996;8:724-730.
Not in our library10.1016/s0955-0674(96)80115-3
336.
Weis S.M., Cheresh D.A. αV integrins in angiogenesis and cancer. Cold Spring Harb. Perspect. Med. 2011;1:a006478.
Not in our library10.1101/cshperspect.a006478
337.
Janiszewska M., Primi M.C., Izard T. Cell adhesion in cancer: Beyond the migration of single cells. J. Biol. Chem. 2020;295:2495-2505.
Not in our library10.1074/jbc.rev119.007759
338.
Truong H., Danen E.H. Integrin switching modulates adhesion dynamics and cell migration. Cell Adhes. Migr. 2009;3:179-181.
Not in our library10.4161/cam.3.2.8036
339.
Zuidema A., Wang W., Sonnenberg A. Crosstalk between cell adhesion complexes in regulation of mechanotransduction. Bioessays. 2020;42:2000119.
Not in our library10.1002/bies.202000119
340.
Kerrisk M.E., Cingolani L.A., Koleske A.J. ECM receptors in neuronal structure, synaptic plasticity, and behavior. Prog. Brain Res. 2014;214:101-131.
Not in our library10.1016/b978-0-444-63486-3.00005-0
341.
Boraschi-Diaz I., Wang J., Mort J.S., Komarova S.V. Collagen type I as a ligand for receptor-mediated signaling. Front. Phys. 2017;5:12.
Not in our library10.3389/fphy.2017.00012
342.
Takai K., Drain A.P., Lawson D.A., Littlepage L.E., Karpuj M., Kessenbrock K., Le A., Inoue K., Weaver V.M., Werb Z. Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers. Genes Dev. 2018;32:244-257.
Not in our library10.1101/gad.301366.117
343.
Gonzalez M.E., Martin E.E., Anwar T., Arellano-Garcia C., Medhora N., Lama A., Chen Y.-C., Tanager K.S., Yoon E., Kidwell K.M. Mesenchymal stem cell-induced DDR2 mediates stromal-breast cancer interactions and metastasis growth. Cell Rep. 2017;18:1215-1228.
Not in our library10.1016/j.celrep.2016.12.079
344.
Bayer S.V., Grither W.R., Brenot A., Hwang P.Y., Barcus C.E., Ernst M., Pence P., Walter C., Pathak A., Longmore G.D. DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. Elife. 2019;8:e45508.
Not in our library10.7554/elife.45508
345.
Liao W.-C., Yen H.-R., Chen C.-H., Chu Y.-H., Song Y.-C., Tseng T.-J., Liu C.-H. CHPF promotes malignancy of breast cancer cells by modifying syndecan-4 and the tumor microenvironment. Am. J. Cancer Res. 2021;11:812.
Not in our library
346.
Leblanc R., Sahay D., Houssin A., Machuca-Gayet I., Peyruchaud O. Autotaxin-β interaction with the cell surface via syndecan-4 impacts on cancer cell proliferation and metastasis. Oncotarget. 2018;9:33170.
Not in our library10.18632/oncotarget.26039
347.
Liu D., Liu T., Li R., Sy M.-S. Mechanisms regulating the binding activity of CD44 to hyaluronic acid. Front. Biosci. Landmark. 1998;3:631-636.
Not in our library10.2741/a307
348.
Naor D. interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front. Immunol. 2016;7:39.
Not in our library10.3389/fimmu.2016.00039
349.
Misra S., Heldin P., Hascall V.C., Karamanos N.K., Skandalis S.S., Markwald R.R., Ghatak S. Hyaluronan–CD44 interactions as potential targets for cancer therapy. FEBS J. 2011;278:1429-1443.
Not in our library10.1111/j.1742-4658.2011.08071.x
350.
Toole B.P. Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin. Cancer Res. 2009;15:7462-7468.
Not in our library10.1158/1078-0432.ccr-09-0479
351.
Jalkanen S., Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J. Cell Biol. 1992;116:817-825.
Not in our library10.1083/jcb.116.3.817
352.
Dzobo K., Sinkala M. Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial–Mesenchymal Transition, and Metastasis. OMICS A J. Integr. Biol. 2021;25:313-332.
Not in our library10.1089/omi.2021.0025
353.
The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer · 2016
No notice
354.
Hirata K., Suzuki H., Imaeda H., Matsuzaki J., Tsugawa H., Nagano O., Asakura K., Saya H., Hibi T. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br. J. Cancer. 2013;109:379-386.
Not in our library10.1038/bjc.2013.314
355.
Palapattu G.S., Wu C., Silvers C.R., Martin H.B., Williams K., Salamone L., Bushnell T., Huang L.S., Yang Q., Huang J. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate. 2009;69:787-798.
Not in our library10.1002/pros.20928
356.
Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G.J., Wada T., Masuko T., Mogushi K., Tanaka H. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat. Commun. 2012;3:1-9.
Not in our library10.1038/ncomms1892
357.
Non-Small Cell Lung Cancer Cells Expressing CD44 Are Enriched for Stem Cell-Like Properties · 2010
No notice
358.
Smith L.R., Cho S., Discher D.E. Stem cell differentiation is regulated by extracellular matrix mechanics. Physiology. 2018;33:16-25.
Not in our library10.1152/physiol.00026.2017
359.
Hoffmann E.J., Ponik S.M. Biomechanical contributions to macrophage activation in the tumor microenvironment. Front. Oncol. 2020;10:787.
Not in our library10.3389/fonc.2020.00787
360.
Chaudhuri O., Cooper-White J., Janmey P.A., Mooney D.J., Shenoy V.B. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature. 2020;584:535-546.
Not in our library10.1038/s41586-020-2612-2
361.
Control of cell morphology and differentiation by substrates with independently tunable elasticity and viscous dissipation · 2018
No notice
362.
Elosegui-Artola A. The extracellular matrix viscoelasticity as a regulator of cell and tissue dynamics. Curr. Opin. Cell Biol. 2021;72:10-18.
Not in our library10.1016/j.ceb.2021.04.002
363.
Tschumperlin D.J., Lagares D. Mechano-therapeutics: Targeting mechanical signaling in fibrosis and tumor stroma. Pharmacol. Ther. 2020;212:107575.
Not in our library10.1016/j.pharmthera.2020.107575
364.
Pratt S.J., Lee R.M., Martin S.S. The mechanical microenvironment in breast cancer. Cancers. 2020;12:1452.
Not in our library10.3390/cancers12061452
365.
Nazemi M., Rainero E. Cross-talk between the tumor microenvironment, extracellular matrix, and cell metabolism in cancer. Front. Oncol. 2020;10:239.
Not in our library10.3389/fonc.2020.00239
366.
Pizzo A.M., Kokini K., Vaughn L.C., Waisner B.Z., Voytik-Harbin S.L. Extracellular matrix (ECM) microstructural composition regulates local cell-ECM biomechanics and fundamental fibroblast behavior: A multidimensional perspective. J. Appl. Physiol. 2005;98:1909-1921.
Not in our library10.1152/japplphysiol.01137.2004
367.
Wala J., Das S. Mapping of biomechanical properties of cell lines on altered matrix stiffness using atomic force microscopy. Biomech. Model. Mechanobiol. 2020;19:1523-1536.
Not in our library10.1007/s10237-019-01285-4
368.
Souza S.T., Agra L.C., Santos C.E., Barreto E., Hickmann J.M., Fonseca E.J. Macrophage adhesion on fibronectin evokes an increase in the elastic property of the cell membrane and cytoskeleton: An atomic force microscopy study. Eur. Biophys. J. 2014;43:573-579.
Not in our library10.1007/s00249-014-0988-3
369.
Park J.S., Burckhardt C.J., Lazcano R., Solis L.M., Isogai T., Li L., Chen C.S., Gao B., Minna J.D., Bachoo R. Mechanical regulation of glycolysis via cytoskeleton architecture. Nature. 2020;578:621-626.
Not in our library10.1038/s41586-020-1998-1
370.
Vitillo L., Kimber S.J. Integrin and FAK regulation of human pluripotent stem cells. Curr. Stem Cell Rep. 2017;3:358-365.
Not in our library10.1007/s40778-017-0100-x
371.
Dedhar S. Cell–substrate interactions and signaling through ILK. Curr. Opin. Cell Biol. 2000;12:250-256.
Not in our library10.1016/s0955-0674(99)00083-6
372.
Schlie-Wolter S., Ngezahayo A., Chichkov B.N. The selective role of ECM components on cell adhesion, morphology, proliferation and communication in vitro. Exp. Cell Res. 2013;319:1553-1561.
Not in our library10.1016/j.yexcr.2013.03.016
373.
Nallanthighal S., Rada M., Heiserman J.P., Cha J., Sage J., Zhou B., Yang W., Hu Y., Korgaonkar C., Hanos C.T. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death Dis. 2020;11:1-12.
Not in our library10.1038/s41419-020-2442-z
374.
Even-Ram S., Yamada K.M. Cell migration in 3D matrix. Curr. Opin. Cell Biol. 2005;17:524-532.
Not in our library10.1016/j.ceb.2005.08.015
375.
Welch D.R., Hurst D.R. Defining the hallmarks of metastasis. Cancer Res. 2019;79:3011-3027.
Not in our library10.1158/0008-5472.can-19-0458
376.
Yilmaz M., Christofori G., Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol. Med. 2007;13:535-541.
Not in our library10.1016/j.molmed.2007.10.004
377.
Conklin M.W., Gangnon R.E., Sprague B.L., Van Gemert L., Hampton J.M., Eliceiri K.W., Bredfeldt J.S., Liu Y., Surachaicharn N., Newcomb P.A. Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In SituCollagen Alignment and Recurrence of DCIS. Cancer Epidemiol. Biomark. Prev. 2018;27:138-145.
Not in our library10.1158/1055-9965.epi-17-0720
378.
Conklin M.W., Eickhoff J.C., Riching K.M., Pehlke C.A., Eliceiri K.W., Provenzano P.P., Friedl A., Keely P.J. Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathol. 2011;178:1221-1232.
Not in our library10.1016/j.ajpath.2010.11.076
379.
Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection · 2016
No notice
380.
Yang N., Friedl A. Syndecan-1-induced ECM fiber alignment requires integrin αvβ3 and syndecan-1 ectodomain and heparan sulfate chains. PLoS ONE. 2016;11:e0150132.
Not in our library10.1371/journal.pone.0150132
381.
Erdogan B., Ao M., White L.M., Means A.L., Brewer B.M., Yang L., Washington M.K., Shi C., Franco O.E., Weaver A.M. Cancer-associated fibroblasts promote directional cancer cell migration by aligning fibronectin. J. Cell Biol. 2017;216:3799-3816.
Not in our library10.1083/jcb.201704053
382.
Ao M., Brewer B.M., Yang L., Franco Coronel O.E., Hayward S.W., Webb D.J., Li D. Stretching fibroblasts remodels fibronectin and alters cancer cell migration. Sci. Rep. 2015;5:1-9.
Not in our library10.1038/srep08334
383.
Feinberg T.Y., Zheng H., Liu R., Wicha M.S., Yu S.M., Weiss S.J. Divergent matrix-remodeling strategies distinguish developmental from neoplastic mammary epithelial cell invasion programs. Dev. Cell. 2018;47:145-160.e6.
Not in our library10.1016/j.devcel.2018.08.025
384.
Jabłońska-Trypuć A., Matejczyk M., Rosochacki S. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J. Enzym. Inhib. Med. Chem. 2016;31:177-183.
Not in our library10.3109/14756366.2016.1161620
385.
Chang C., Werb Z. The many faces of metalloproteases: Cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. 2001;11:S37-S43.
Not in our library10.1016/s0962-8924(01)02122-5
386.
Elia I., Rossi M., Stegen S., Broekaert D., Doglioni G., van Gorsel M., Boon R., Escalona-Noguero C., Torrekens S., Verfaillie C. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 2019;568:117-121.
Not in our library10.1038/s41586-019-0977-x
387.
Ge J., Cui H., Xie N., Banerjee S., Guo S., Dubey S., Barnes S., Liu G. Glutaminolysis promotes collagen translation and stability via α-ketoglutarate–mediated mTOR activation and proline hydroxylation. Am. J. Respir. Cell Mol. Biol. 2018;58:378-390.
Not in our library10.1165/rcmb.2017-0238oc
388.
Micalizzi D.S., Maheswaran S., Haber D.A. A conduit to metastasis: Circulating tumor cell biology. Genes Dev. 2017;31:1827-1840.
Not in our library10.1101/gad.305805.117
389.
Peinado H., Zhang H., Matei I.R., Costa-Silva B., Hoshino A., Rodrigues G., Psaila B., Kaplan R.N., Bromberg J.F., Kang Y. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer. 2017;17:302-317.
Not in our library10.1038/nrc.2017.6
390.
Gao Y., Bado I., Wang H., Zhang W., Rosen J.M., Zhang X.H.-F. Metastasis organotropism: Redefining the congenial soil. Dev. Cell. 2019;49:375-391.
Not in our library10.1016/j.devcel.2019.04.012
391.
Platelets reduce anoikis and promote metastasis by activating YAP1 signaling · 2017
No notice
392.
Yu M., Ting D.T., Stott S.L., Wittner B.S., Ozsolak F., Paul S., Ciciliano J.C., Smas M.E., Winokur D., Gilman A.J. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012;487:510-513.
Not in our library10.1038/nature11217
393.
Pantel K., Alix-Panabières C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009;6:339-351.
Not in our library10.1038/nrclinonc.2009.44
394.
Goddard E.T., Bozic I., Riddell S.R., Ghajar C.M. Dormant tumour cells, their niches and the influence of immunity. Nat. Cell Biol. 2018;20:1240-1249.
Not in our library10.1038/s41556-018-0214-0
395.
Yeh A.C., Ramaswamy S. Mechanisms of cancer cell dormancy—Another hallmark of cancer? Cancer Res. 2015;75:5014-5022.
Not in our library10.1158/0008-5472.can-15-1370
396.
Boire A., Coffelt S.B., Quezada S.A., Vander Heiden M.G., Weeraratna A.T. Tumour dormancy and reawakening: Opportunities and challenges. Trends Cancer. 2019;5:762-765.
Not in our library10.1016/j.trecan.2019.10.010
397.
Phan T.G., Croucher P.I. The dormant cancer cell life cycle. Nat. Rev. Cancer. 2020;20:398-411.
Not in our library10.1038/s41568-020-0263-0
398.
Gay L.J., Malanchi I. The sleeping ugly: Tumour microenvironment’s act to make or break the spell of dormancy. Biochim. Et Biophys. Acta Rev. Cancer. 2017;1868:231-238.
Not in our library10.1016/j.bbcan.2017.05.002
399.
Ghajar C.M., Peinado H., Mori H., Matei I.R., Evason K.J., Brazier H., Almeida D., Koller A., Hajjar K.A., Stainier D.Y. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013;15:807-817.
Not in our library10.1038/ncb2767
400.
Mancini M.L., Sonis S.T. Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Front. Pharmacol. 2014;5:51.
Not in our library10.3389/fphar.2014.00051
401.
Principe D.R., Narbutis M., Kumar S., Park A., Viswakarma N., Dorman M.J., Kamath S.D., Grippo P.J., Fishel M.L., Hwang R.F. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination ImmunotherapyGemcitabine Primes Pancreatic Cancer for Immunotherapy. Cancer Res. 2020;80:3101-3115.
Not in our library10.1158/0008-5472.can-19-2959
402.
Shen C.J., Sharma A., Vuong D.-V., Erler J.T., Pruschy M., Broggini-Tenzer A. Ionizing radiation induces tumor cell lysyl oxidase secretion. BMC Cancer. 2014;14:1-10.
Not in our library10.1186/1471-2407-14-532
403.
Roy D.M., Walsh L.A. Candidate prognostic markers in breast cancer: Focus on extracellular proteases and their inhibitors. Breast Cancer Targets Ther. 2014;6:81.
Not in our library10.2147/bctt.s46020
404.
Kanayama H.o., Yokota K.y., Kurokawa Y., Murakami Y., Nishitani M., Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer Interdiscip. Int. J. Am. Cancer Soc. 1998;82:1359-1366.
Not in our library
405.
Bergamaschi A., Tagliabue E., Sørlie T., Naume B., Triulzi T., Orlandi R., Russnes H., Nesland J., Tammi R., Auvinen P. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J. Pathol. 2008;214:357-367.
Not in our library10.1002/path.2278
406.
Valdembri D., Serini G. The roles of integrins in cancer. Fac. Rev. 2021;10:45.
Not in our library10.12703/r/10-45
407.
Acerbi I., Cassereau L., Dean I., Shi Q., Au A., Park C., Chen Y.Y., Liphardt J., Hwang E.S., Weaver V.M. Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr. Biol. 2015;7:1120-1134.
Not in our library10.1039/c5ib00040h
408.
Bordeleau F., Mason B.N., Lollis E.M., Mazzola M., Zanotelli M.R., Somasegar S., Califano J.P., Montague C., LaValley D.J., Huynh J., et al. Matrix stiffening promotes a tumor vasculature phenotype. Proc. Natl. Acad. Sci. USA. 2017;114:492-497.
Not in our library10.1073/pnas.1613855114
409.
Hui L., Zhang J., Ding X., Guo X., Jiang X. Matrix stiffness regulates the proliferation, stemness and chemoresistance of laryngeal squamous cancer cells. Int. J. Oncol. 2017;50:1439-1447.
Not in our library10.3892/ijo.2017.3877
410.
McLane J.S., Ligon L.A. Stiffened Extracellular Matrix and Signaling from Stromal Fibroblasts via Osteoprotegerin Regulate Tumor Cell Invasion in a 3-D Tumor in Situ Model. Cancer Microenviron. 2016;9:127-139.
Not in our library10.1007/s12307-016-0188-z
411.
Tadeo I., Berbegall A.P., Navarro S., Castel V., Noguera R. A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors. Pediatr. Blood Cancer. 2017;64:e26449.
Not in our library10.1002/pbc.26449
412.
Qin X., Lv X., Li P., Yang R., Xia Q., Chen Y., Peng Y., Li L., Li S., Li T. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells. Biochim. Et Biophys. Acta Mol. Basis Dis. 2020;1866:165625.
Not in our library10.1016/j.bbadis.2019.165625
413.
Wang D., Li Y., Ge H., Ghadban T., Reeh M., Güngör C. The Extracellular Matrix: A Key Accomplice of Cancer Stem Cell Migration, Metastasis Formation, and Drug Resistance in PDAC. Cancers. 2022;14:3998.
Not in our library10.3390/cancers14163998
414.
Grantab R.H., Tannock I.F. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer. 2012;12:214.
Not in our library10.1186/1471-2407-12-214
415.
Harisi R., Jeney A. Extracellular matrix as target for antitumor therapy. OncoTargets Ther. 2015;8:1387-1398.
Not in our library10.2147/ott.s48883
416.
Holle A.W., Young J.L., Spatz J.P. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. Adv. Drug Deliv. Rev. 2016;97:270-279.
Not in our library10.1016/j.addr.2015.10.007
417.
Tissue mechanics promote IDH1-dependent HIF1α–tenascin C feedback to regulate glioblastoma aggression · 2016
Corrected
418.
Mittal V., El Rayes T., Narula N., McGraw T.E., Altorki N.K., Barcellos-Hoff M.H. The Microenvironment of Lung Cancer and Therapeutic Implications. Adv. Exp. Med. Biol. 2016;890:75-110.
Not in our library10.1007/978-3-319-24932-2_5
419.
Mumenthaler S.M., Foo J., Choi N.C., Heise N., Leder K., Agus D.B., Pao W., Michor F., Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inf. 2015;14:19-31.
Not in our library10.4137/cin.s19338
420.
Nieponice A., McGrath K., Qureshi I., Beckman E.J., Luketich J.D., Gilbert T.W., Badylak S.F. An extracellular matrix scaffold for esophageal stricture prevention after circumferential EMR. Gastrointest. Endosc. 2009;69:289-296.
Not in our library10.1016/j.gie.2008.04.022
421.
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells · 2017
No notice
422.
Brechbuhl H.M., Finlay-Schultz J., Yamamoto T., Gillen A., Cittelly D.M., Tan A.C., Sams S.B., Pillai M., Elias A., Robinson W.A., et al. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016;23:1710-1721.
Not in our library10.1158/1078-0432.ccr-15-2851
423.
Cui L., Tse K., Zahedi P., Harding S.M., Zafarana G., Jaffray D.A., Bristow R.G., Allen C. Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. Radiat. Res. 2014;182:475-488.
Not in our library10.1667/rr13642.1
424.
Cun X., Ruan S., Chen J., Zhang L., Li J., He Q., Gao H. A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan. Acta Biomater. 2016;31:186-196.
Not in our library10.1016/j.actbio.2015.12.002
425.
Lu P., Weaver V.M., Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012;196:395-406.
Not in our library10.1083/jcb.201102147
426.
Sung S.Y., Hsieh C.L., Wu D., Chung L.W., Johnstone P.A. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr. Probl. Cancer. 2007;31:36-100.
Not in our library10.1016/j.currproblcancer.2006.12.002
427.
Whatcott C.J., Han H., Posner R.G., Hostetter G., Von Hoff D.D. Targeting the tumor microenvironment in cancer: Why hyaluronidase deserves a second look. Cancer Discov. 2011;1:291-296.
Not in our library10.1158/2159-8290.cd-11-0136
428.
Mbeunkui F., Johann D.J. Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother. Pharmacol. 2009;63:571-582.
Not in our library10.1007/s00280-008-0881-9
429.
Xiao Q., Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron. 2012;5:261-273.
Not in our library10.1007/s12307-012-0105-z
430.
Gao Y., Xiao Q., Ma H., Li L., Liu J., Feng Y., Fang Z., Wu J., Han X., Zhang J. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc. Natl. Acad. Sci. USA. 2010;107:18892-18897.
Not in our library10.1073/pnas.1004952107
431.
Vallet S.D., Ricard-Blum S. Lysyl oxidases: From enzyme activity to extracellular matrix cross-links. Essays Biochem. 2019;63:349-364.
Not in our library10.1042/ebc20180050
432.
Seewaldt V. ECM stiffness paves the way for tumor cells. Nat. Med. 2014;20:332-333.
Not in our library10.1038/nm.3523
433.
Sato S., Chong S.G., Upagupta C., Yanagihara T., Saito T., Shimbori C., Bellaye P.-S., Nishioka Y., Kolb M.R. Fibrotic extracellular matrix induces release of extracellular vesicles with pro-fibrotic miRNA from fibrocytes. Thorax. 2021;76:895-906.
Not in our library10.1136/thoraxjnl-2020-215962
434.
Netti P.A., Baxter L.T., Boucher Y., Skalak R., Jain R.K. Time-dependent behavior of interstitial fluid pressure in solid tumors: Implications for drug delivery. Cancer Res. 1995;55:5451-5458.
Not in our library
435.
Morin P.J. Drug resistance and the microenvironment: Nature and nurture. Drug Resist. Updat. 2003;6:169-172.
Not in our library10.1016/s1368-7646(03)00059-1
436.
Gouarderes S., Mingotaud A.-F., Vicendo P., Gibot L. Vascular and extracellular matrix remodeling by physical approaches to improve drug delivery at the tumor site. Expert Opin. Drug Deliv. 2020;17:1703-1726.
Not in our library10.1080/17425247.2020.1814735
437.
Stylianopoulos T., Munn L.L., Jain R.K. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: From mathematical modeling to bench to bedside. Trends Cancer. 2018;4:292-319.
Not in our library10.1016/j.trecan.2018.02.005
438.
Sercu S., Zhang L., Merregaert E.J. The extracellular matrix protein 1: Its molecular interaction and implication in tumor progression. Cancer Investig. 2008;26:375-384.
Not in our library10.1080/07357900701788148
439.
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure · 2018
No notice
440.
Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 2003;9:207-214.
Not in our library
441.
Biaoxue R., Xiguang C., Hua L., Hui M., Shuanying Y., Wei Z., Wenli S., Jie D. Decreased expression of decorin and p57 (KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int. J. Biol. Mrk. 2011;26:9-21.
Not in our library10.5301/jbm.2011.6372
442.
Matsumine A., Shintani K., Kusuzaki K., Matsubara T., Satonaka H., Wakabayashi T., Iino T., Uchida A. Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J. Surg. Oncol. 2007;96:411-418.
Not in our library10.1002/jso.20745
443.
Järveläinen H., Sainio A., Koulu M., Wight T.N., Penttinen R. Extracellular matrix molecules: Potential targets in pharmacotherapy. Pharmacol. Rev. 2009;61:198-223.
Not in our library10.1124/pr.109.001289
444.
Erkan M., Michalski C.W., Rieder S., Reiser–Erkan C., Abiatari I., Kolb A., Giese N.A., Esposito I., Friess H., Kleeff J. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 2008;6:1155-1161.
Not in our library10.1016/j.cgh.2008.05.006
445.
Niland S., Eble J.A. Hold on or cut? Integrin-and MMP-mediated cell–matrix interactions in the tumor microenvironment. Int. J. Mol. Sci. 2020;22:238.
Not in our library10.3390/ijms22010238
446.
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy · 2020
No notice
447.
Hanker A.B., Estrada M.V., Bianchini G., Moore P.D., Zhao J., Cheng F., Koch J.P., Gianni L., Tyson D.R., Sánchez V. Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast CancerECM Promotes Resistance to HER2/PI3K Inhibition. Cancer Res. 2017;77:3280-3292.
Not in our library10.1158/0008-5472.can-16-2808
448.
Hingorani S.R., Zheng L., Bullock A.J., Seery T.E., Harris W.P., Sigal D.S., Braiteh F., Ritch P.S., Zalupski M.M., Bahary N. HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 2018;36:359-366.
Not in our library10.1200/jco.2017.74.9564
449.
Ramanathan R.K., McDonough S.L., Philip P.A., Hingorani S.R., Lacy J., Kortmansky J.S., Thumar J., Chiorean E.G., Shields A.F., Behl D. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J. Clin. Oncol. 2019;37:1062.
Not in our library10.1200/jco.18.01295
450.
Lokeshwar B.L. MMP inhibition in prostate cancer. Ann. N. Y. Acad. Sci. 1999;878:271-289.
Not in our library10.1111/j.1749-6632.1999.tb07690.x
451.
Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and-9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie. 2005;87:287-297.
Not in our library10.1016/j.biochi.2005.01.014
452.
TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells · 2012
No notice
453.
Matter H., Schudok M. Recent advances in the design of matrix metalloprotease inhibitors. Curr. Opin. Drug Discov. Dev. 2004;7:513-535.
Not in our library
454.
Nuti E., Tuccinardi T., Rossello A. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Des. 2007;13:2087-2100.
Not in our library10.2174/138161207781039706
455.
Mannello F., Tonti G., Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets. 2005;5:285-298.
Not in our library10.2174/1568009054064615
456.
Radisky E.S., Raeeszadeh-Sarmazdeh M., Radisky D.C. Therapeutic potential of matrix metalloproteinase inhibition in breast cancer. J. Cell. Biochem. 2017;118:3531-3548.
Not in our library10.1002/jcb.26185
457.
Devel L., Czarny B., Beau F., Georgiadis D., Stura E., Dive V. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1’ cavity. Biochimie. 2010;92:1501-1508.
Not in our library10.1016/j.biochi.2010.07.017
458.
Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies · 2015
No notice
459.
Grant S. Cotargeting survival signaling pathways in cancer. J. Clin. Investig. 2008;118:3003-3006.
Not in our library10.1172/jci36898e1
460.
Xu J., Zhou J.-Y., Wei W.-Z., Wu G.S. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS ONE. 2010;5:e10226.
Not in our library10.1371/journal.pone.0010226
461.
Roy-Luzarraga M., Hodivala-Dilke K. Molecular Pathways: Endothelial Cell FAK—A Target for Cancer TreatmentEndothelial Cell FAK in Cancer Treatment. Clin. Cancer Res. 2016;22:3718-3724.
Not in our library10.1158/1078-0432.ccr-14-2021
462.
McCormick F. Small-molecule inhibitors of cell signaling. Curr. Opin. Biotechnol. 2000;11:593-597.
Not in our library10.1016/s0958-1669(00)00149-x
463.
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma · 2014
No notice
464.
Lin R., Yi S., Gong L., Liu W., Wang P., Liu N., Zhao L., Wang P. Inhibition of TGF-β signaling with halofuginone can enhance the antitumor effect of irradiation in Lewis lung cancer. OncoTargets Ther. 2015;8:3549.
Not in our library10.2147/ott.s92518
465.
Juárez P., Mohammad K.S., Yin J.J., Fournier P.G., McKenna R.C., Davis H.W., Peng X.H., Niewolna M., Javelaud D., Chirgwin J.M. Halofuginone Inhibits the Establishment and Progression of Melanoma Bone MetastasesHalofuginone Decreases Melanoma Bone Metastases. Cancer Res. 2012;72:6247-6256.
Not in our library10.1158/0008-5472.can-12-1444
466.
Miyazono K. Transforming growth factor-β signaling in epithelial-mesenchymal transition and progression of cancer. Proc. Jpn. Acad. Ser. B. 2009;85:314-323.
Not in our library10.2183/pjab.85.314
467.
Shaty M.H., Arif I.S., Al-Ezzi M.I., Hanna D.B. Metformin attenuate fibrosis in both acute and chronic doxorubicin cardiotoxicity in rabbits. J. Pharm. Sci. Res. 2018;10:1559-1565.
Not in our library
468.
Lampi M.C., Reinhart-King C.A. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Sci. Transl. Med. 2018;10:eaao0475.
Not in our library10.1126/scitranslmed.aao0475
469.
Sporn M.B., Roberts A.B., Wakefield L.M., Assoian R.K. Transforming growth factor-β: Biological function and chemical structure. Science. 1986;233:532-534.
Not in our library10.1126/science.3487831
470.
Krane S.M. Collagenases and collagen degradation. J. Investig. Dermatol. 1982;79:83-86.
Not in our library10.1038/jid.1982.16
471.
McKee T.D., Grandi P., Mok W., Alexandrakis G., Insin N., Zimmer J.P., Bawendi M.G., Boucher Y., Breakefield X.O., Jain R.K. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006;66:2509-2513.
Not in our library10.1158/0008-5472.can-05-2242
472.
Parks W.C., Wilson C.L., López-Boado Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004;4:617-629.
Not in our library10.1038/nri1418
473.
Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol. 2013;13:649-665.
Not in our library10.1038/nri3499
474.
Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 2007;8:221-233.
Not in our library10.1038/nrm2125
475.
Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer—Trials and tribulations. Science. 2002;295:2387-2392.
Not in our library10.1126/science.1067100
476.
Castellani P., Viale G., Dorcaratto A., Nicolo G., Kaczmarek J., Querze G., Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis. Int. J. Cancer. 1994;59:612-618.
Not in our library10.1002/ijc.2910590507
477.
Glukhova M.A., Frid M.G., Shekhonin B.V., Balabanov Y.V., Koteliansky V.E. Expression of fibronectin variants in vascular and visceral smooth muscle cells in development. Dev. Biol. 1990;141:193-202.
Not in our library10.1016/0012-1606(90)90114-x
478.
Han Z., Lu Z.-R. Targeting fibronectin for cancer imaging and therapy. J. Mater. Chem. B. 2017;5:639-654.
Not in our library10.1039/c6tb02008a
479.
Carnemolla B., Leprini A., Allemanni G., Saginati M., Zardi L. The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J. Biol. Chem. 1992;267:24689-24692.
Not in our library10.1016/s0021-9258(18)35819-8
480.
Lo K.-M., Lan Y., Lauder S., Zhang J., Brunkhorst B., Qin G., Verma R., Courtenay-Luck N., Gillies S.D. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol. Immunother. 2007;56:447-457.
Not in our library10.1007/s00262-006-0203-1
481.
Saw P.E., Kim S., Lee I.-h., Park J., Yu M., Lee J., Kim J.-I., Jon S. Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J. Mater. Chem. B. 2013;1:4723-4726.
Not in our library10.1039/c3tb20815j
482.
Lokman N.A., Price Z.K., Hawkins E.K., Macpherson A.M., Oehler M.K., Ricciardelli C. 4-Methylumbelliferone inhibits cancer stem cell activation and overcomes chemoresistance in ovarian cancer. Cancers. 2019;11:1187.
Not in our library10.3390/cancers11081187
483.
Kohli A.G., Kivimäe S., Tiffany M.R., Szoka F.C. Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan. J. Control. Release. 2014;191:105-114.
Not in our library10.1016/j.jconrel.2014.05.019
484.
Doherty G.J., Tempero M., Corrie P.G. HALO-109–301: A Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer. Future Oncol. 2018;14:13-22.
Not in our library10.2217/fon-2017-0338
485.
Schnittert J., Bansal R., Storm G., Prakash J. Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Adv. Drug Deliv. Rev. 2018;129:37-53.
Not in our library10.1016/j.addr.2018.01.020
486.
Gutheil J.C., Campbell T.N., Pierce P.R., Watkins J.D., Huse W.D., Bodkin D.J., Cheresh D.A. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin ανβ3. Clin. Cancer Res. 2000;6:3056-3061.
Not in our library
487.
Raguse J.-D., Gath H.J., Bier J., Riess H., Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol. 2004;40:228-230.
Not in our library10.1016/j.oraloncology.2003.08.003
488.
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation · 2010
No notice
489.
Tijink B.M., Buter J., De Bree R., Giaccone G., Lang M.S., Staab A., Leemans C.R., Van Dongen G.A. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin. Cancer Res. 2006;12:6064-6072.
Not in our library10.1158/1078-0432.ccr-06-0910
490.
Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., Erhardt T., Gronau S. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol. 2008;44:823-829.
Not in our library10.1016/j.oraloncology.2007.10.009
491.
Liu S., Qin S., He M., Zhou D., Qin Q., Wang H. Current applications of poly (lactic acid) composites in tissue engineering and drug delivery. Compos. Part B Eng. 2020;199:108238.
Not in our library10.1016/j.compositesb.2020.108238
492.
Zhang M., Liang J., Yang Y., Liang H., Jia H., Li D. Current trends of targeted drug delivery for oral cancer therapy. Front. Bioeng. Biotechnol. 2020;8:618931.
Not in our library10.3389/fbioe.2020.618931
493.
Meng Z., Liu Y., Xu K., Sun X., Yu Q., Wu Z., Zhao Z. Biomimetic polydopamine-modified silk fibroin/curcumin nanofibrous scaffolds for chemo-photothermal therapy of bone tumor. ACS Omega. 2021;6:22213-22223.
Not in our library10.1021/acsomega.1c02903
494.
Ozcelikkale A., Moon H.r., Linnes M., Han B. In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2017;9:e1460.
Not in our library10.1002/wnan.1460
495.
Wang L., Huo M., Chen Y., Shi J. Tumor microenvironment-enabled nanotherapy. Adv. Healthc. Mater. 2018;7:1701156.
Not in our library10.1002/adhm.201701156
496.
Sheikhpour M., Barani L., Kasaeian A. Biomimetics in drug delivery systems: A critical review. J. Control. Release. 2017;253:97-109.
Not in our library10.1016/j.jconrel.2017.03.026
497.
Frith J.E., Thomson B., Genever P.G. Dynamic three-dimensional culture methods enhance mesenchymal stem cell properties and increase therapeutic potential. Tissue Eng. Part C Methods. 2010;16:735-749.
Not in our library10.1089/ten.tec.2009.0432
498.
Martino M.M., Briquez P.S., Güç E., Tortelli F., Kilarski W.W., Metzger S., Rice J.J., Kuhn G.A., Müller R., Swartz M.A. Growth factors engineered for super-affinity to the extracellular matrix enhance tissue healing. Science. 2014;343:885-888.
Not in our library10.1126/science.1247663
499.
Gjorgieva D., Zaidman N., Bosnakovski D. Mesenchymal stem cells for anti-cancer drug delivery. Recent Pat. Anti-Cancer Drug Discov. 2013;8:310-318.
Not in our library10.2174/15748928113089990040
500.
Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E., Andreeff M. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 2004;96:1593-1603.
Not in our library10.1093/jnci/djh299
501.
Dzobo K. Recent trends in multipotent human mesenchymal stem/stromal cells: Learning from history and advancing clinical applications. OMICS A J. Integr. Biol. 2021;25:342-357.
Not in our library10.1089/omi.2021.0049
502.
Corrêa L.H., Heyn G.S., Magalhaes K.G. The impact of the adipose organ plasticity on inflammation and cancer progression. Cells. 2019;8:662.
Not in our library10.3390/cells8070662
503.
Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment · 2018
No notice
504.
Gao P., Ding Q., Wu Z., Jiang H., Fang Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 2010;290:157-166.
Not in our library10.1016/j.canlet.2009.08.031
505.
Bu S., Wang Q., Zhang Q., Sun J., He B., Xiang C., Liu Z., Lai D. Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells. Sci. Rep. 2016;6:37019.
Not in our library10.1038/srep37019
506.
Rasti Boroojeni F., Mashayekhan S., Abbaszadeh H.-A., Ansarizadeh M., Khoramgah M.-S., Rahimi Movaghar V. Bioinspired nanofiber scaffold for differentiating bone marrow-derived neural stem cells to oligodendrocyte-like cells: Design, fabrication, and characterization. Int. J. Nanomed. 2020;15:3903-3920.
Not in our library10.2147/ijn.s248509
507.
Chen C., Tang J., Gu Y., Liu L., Liu X., Deng L., Martins C., Sarmento B., Cui W., Chen L. Bioinspired hydrogel electrospun fibers for spinal cord regeneration. Adv. Funct. Mater. 2019;29:1806899.
Not in our library10.1002/adfm.201806899
508.
Ahmadi S., Nasiri M., Pourrajab-miandoab A., Abbasi F., Hassanpour F., Sabzi E. Photo-and thermo-responsive extracellular matrix mimicking nano-coatings prepared from poly (N-isopropylacrylamide)-spiropyran copolymer for effective cell sheet harvesting. Prog. Org. Coat. 2022;167:106847.
Not in our library10.1016/j.porgcoat.2022.106847
509.
Valente K.P., Thind S.S., Akbari M., Suleman A., Brolo A.G. Collagen Type I–Gelatin Methacryloyl Composites: Mimicking the Tumor Microenvironment. ACS Biomater. Sci. Eng. 2019;5:2887-2898.
Not in our library10.1021/acsbiomaterials.9b00264
510.
Zhou H., Fan Z., Deng J., Lemons P.K., Arhontoulis D.C., Bowne W.B., Cheng H. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy. Nano Lett. 2016;16:3268-3277.
Not in our library10.1021/acs.nanolett.6b00820
511.
Şen Ö., Emanet M., Ciofani G. Nanotechnology-Based Strategies to Evaluate and Counteract Cancer Metastasis and Neoangiogenesis. Adv. Healthc. Mater. 2021;10:2002163.
Not in our library10.1002/adhm.202002163
512.
Zamani M., Prabhakaran M.P., Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int. J. Nanomed. 2013;8:2997-3017.
Not in our library10.2147/ijn.s43575
513.
Fu Y., Li X., Ren Z., Mao C., Han G. Multifunctional electrospun nanofibers for enhancing localized cancer treatment. Small. 2018;14:1801183.
Not in our library10.1002/smll.201801183
514.
Lee H.J., Mun S., Pham D.M., Kim P. Extracellular matrix-based hydrogels to tailoring tumor organoids. ACS Biomater. Sci. Eng. 2021;7:4128-4135.
Not in our library10.1021/acsbiomaterials.0c01801
515.
Votanopoulos K.I., Forsythe S., Sivakumar H., Mazzocchi A., Aleman J., Miller L., Levine E., Triozzi P., Skardal A. Model of patient-specific immune-enhanced organoids for immunotherapy screening: Feasibility study. Ann. Surg. Oncol. 2020;27:1956-1967.
Not in our library10.1245/s10434-019-08143-8
516.
Stirling E., Willey-Shelkey E., Wilson A., Skardal A., Triozzi P., Terabe M., Miller L., Soker S., Soto-Pantoja D. 206 An immune-competent tumor organoid platform to test novel immune checkpoint combinations targeting the receptor CD47 in triple negative breast cancer. J. Immunother. Cancer. 2020;8:A121-A122.
Not in our library
517.
Tang R.-Z., Liu Z.-Z., Gu S.-S., Liu X.-Q. Multiple local therapeutics based on nano-hydrogel composites in breast cancer treatment. J. Mater. Chem. B. 2021;9:1521-1535.
Not in our library10.1039/d0tb02737e
518.
Li A., Zhao J., Fu J., Cai J., Zhang P. Recent advances of biomimetic nano-systems in the diagnosis and treatment of tumor. Asian J. Pharm. Sci. 2021;16:161-174.
Not in our library10.1016/j.ajps.2019.08.001
519.
Oliveira M., Conceição P., Kant K., Ainla A., Diéguez L. Electrochemical sensing in 3D cell culture models: New Tools for developing better cancer diagnostics and treatments. Cancers. 2021;13:1381.
Not in our library10.3390/cancers13061381

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.